Bottom up proteomics of cryptocyanin protein and anti-tumor Thomsen–Friedenreich neoglycoconjugate vaccine by Demian, Wael
Bottom up proteomics of cryptocyanin protein and anti-tumor 
Thomsen–Friedenreich neoglycoconjugate vaccine 
 
  
 
 
 
by 
 
 
Wael Demian 
 
 
 
A thesis submitted to the 
School of Graduate Studies in partial fulfillment of the requirements for the degree of 
Master of Science  
 
 
 
  
 
May 2015 
 
 
 
 
 
Department of Biochemistry 
Memorial University of Newfoundland 
 
 
 
 
St. John’s                                                                                                        Newfoundland 
 
ii 
 
ABSTRACT 
 
In this thesis, two different kinds of complex biomolecules were examined: 
cryptocyanin protein of snow crab (Chionoecetes opilio) and carbohydrate-protein 
neoglycoconjugate vaccine using mass spectrometry (MS) and tandem mass spectrometry 
(MS/MS). 
The main objective of the first study was to determine structural changes in snow 
crab cryptocyanin protein. Accordingly, cryptocyanin was isolated and purified from 
molting and non molting snow crabs. The purified molting and non molting 
cryptocyanins were sequenced by using matrix assisted laser desorption/ionization mass 
spectrometry (MALDI-MS) and collsion induced dissocation tandem mass spectrometry 
(CID-MS/MS). The structural differences between molting and non-molting cryptocyanin 
were reported using bottom-up proteomics. The molecular masses of the snow crab 
during molting and non-molting stages were found to be respectively 67.6 kDa and 68.1 
kDa. 
 In the second study, two anti-tumor Thomsen-Friedenreich neoglycoconjugate 
vaccines were prepared by the Michael addition reaction, and their molecular composition 
was confirmed by MALDI-TOF-MS analysis. De novo peptide sequencing using 
electrospray ionization in the positive ion mode mass spectrometry (ESI-MS, + ion mode) 
and low-energy CID-MS/MS of trypsin digests using a quadrupole-quadrupole-time of 
flight –hybrid tandem mass spectrometer (QqTOF-MS/MS). The CID-analysis allowed us 
to identify three glycation sites for the glycoconjugate prepared with a TF: protein ratio of 
2:1, and 14 glycation sites for the glycoconjugate prepared with a TF: protein ratio of 8:1. 
It should be noted that this work represents the only published report for the 
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determination of the exact poistions of the carbohydrate haptens on this  unique C-S 
linked glycoconjugate. In addition, this investigation constitutes a versatile example for 
the identification of accurate quality control necessary in commercial production of 
glycoconjugate vaccines. Indeed, the glycopeptides isolated were fully characterized 
during this work and may well represent useful reference compounds that can be used in 
standardization analyses.
 
The presented two applications of this research indicate that the cohesive and 
clever application of MS continue to grow due to its high sensitivity, and its ability to 
analyze high molecular mass biomolecules such as the two complex biomolecules.   
In summary this thesis has presented a major dynamic role for the identification, 
characterization and sequencing of two novel complex biomolecules namely the molting 
and non molting and cryptocyanin proteins and the two anti-tumor Thomsen-Friedenreich 
neoglycoconjugate vaccines. These biomolecules were chosen as elegant applications of 
MS/MS in the fields of proteomics and glycomics vaccine. 
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Chapter I: Introduction 
1.1 Mass spectrometry 
 Mass spectrometry (MS) is an outstanding analytical technique for the 
characterization of different biomolecules ranging from small (such as sugars) to larger 
molecules (such as proteins).
[1-10] 
Thus, MS is extensively used in proteomics,
[1] 
glycomics,
[2] 
metabolomics,
[3] 
lipidomics,
[4]
 and in oligonucleotide analysis.
[5]
  It is used 
for determining the molecular mass of chemical or biological compounds.
[1-10] 
Additionally, it is an exceptional technique for elucidating the structure of 
biomolecules.
[7-10] 
This technique holds an integral place among all analytical techniques 
due to its sensitivity, its low sample consumption, and its relative rapidity of analysis.
[8-10]
 
 MS determines the mass of molecules, whereby an electrical charge is placed on 
the molecule and the resulting ions are separated by their mass to charge ratio (m/z).
[1-10]
 
The mass spectrometer is typically composed of three main parts: the ionization source, 
the analyzer, and the detector (Figure 1.1).
[11]
 In the ionization source, the molecule is 
heated to a certain temperature, and then it undergoes ionization under  atmospheric 
pressure in the case of electrospray ionization (ESI), atmospheric pressure 
photoionization (APPI) and atmospheric pressure chemical ionization (APCI). 
Conversely, the molecule undergoes ionization under a vacuum in the case of matrix 
assisted laser desorption ionization (MALDI), chemical ionization (CI), and electron 
ionization (EI). These ionization sources are conducted in a low pressure vacuum in order 
to minimize collision of ions with gas molecules. It is in the ionization source that the 
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ions are created. In the analyzer, the molecular and fragment ions are essentially 
separated according to their m/z. Finally, the detector collects ions, quantifies their 
intensities and amplifies their signals.
[6-8]
 After the detector, a computer system processes 
the data and generates a mass spectrum, which specifies the variation of ion current 
observed according to the m/z ratio. The ionization sources, the analyzers, and the 
detectors can be oriented in a variety of configurations and accordingly can create a 
variety of mass spectrometer types.
[6]
 However, the choice of ionization source and 
analyzer type will depend on the nature of the sample and on the data type desired 
(spectrum or image).
[6-8]
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Figure 1.1 Components of a mass spectrometer. The ion source, mass analyzer and 
detector are conducted under high vacuum in case of MALDI, CI and EI, but at the 
atmospheric pressure in case of ESI, APPI and APCI. 
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1.1.1 Types of ionization techniques 
 The ionization techniques are classified into hard ionization techniques and soft 
ionization techniques. The terminology of hard and soft is related to the internal energy 
used for the formation of ions from the analyte.
[12-15]
 High internal energy is used in the 
hard techniques such as CI and EI.
[12-14]
 Alternatively, a low internal energy has been 
used in soft techniques such as MALDI, ESI, fast atom bombardment (FAB), APPI, 
APCI, and more recently, desorption electrospray ionization (DESI).
[14,15]
  
 Both EI and CI are traditional techniques, working under high vacuum. In addition 
these techniques have been used for small molecular masses.
[12-15]
 They can also be 
coupled with gas chromatography (GC) instrument, so the sample can be introduced into 
the source in the gas phase. 
In EI, a molecule “M” is bombarded with energetic electrons that are produced by 
heating a tungsten wire with an internal energy of typically 70 eV.
[12-14]
 The electrons 
react in the gas phase with the analyte (M) to produce a radical cation: 
M + e
-
 → M+· + 2e- 
In CI, ions are generated by the interaction between a molecule “M” and a 
reactive gas like methane.
[14,15]
 Unlike EI which generates a radical cation, CI produces 
protonated molecules [M+H]
+
. The ion protonation occurs through two steps: the first 
step involves a bombardment of electrons with a neutral gas (example: methane, CH4) 
with an electron, and the second step is the protonation of the molecule “M” by the 
reactive gas which is generated from the first step.  
CH4 + e
-
 → CH4
+·
 + 2e
-
 
CH4 + CH4
+·
 → CH5
+
 + CH3
·
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M + CH5
+
 → [M + H]+ + CH4  
CI is a softer method than EI, because there is generally less energy deposited into the 
newly formed ion, and accordingly there is generally less analyte fragmentation, although 
it is still considered to be a hard technique.
[14,15]
 Because of the smaller amounts of 
fragmentation, the mass spectra generated by CI are generally simpler that generated by 
EI, and interpretation easier.
[14,15]
 In this thesis, MALDI and ESI were used for the 
structural characterization of different biomolecules. 
1.1.2 Matrix assisted laser desorption ionization (MALDI) 
 MALDI is a soft ionization technique which was revolutionized analysis of large 
biomolecules.
[16]
 It is widely used for the analysis of large biomolecules with 
conventional single stage direct MS analyzers (example: MS analysis of intact protein)  
and tandem mass spectrometry using collision induced dissociation (CID-MS/MS).
[6-21]
 
MALDI is well-suited for the direct analysis of biomolecules due to its high sensitivity, 
and high tolerance for salts and other contaminants.
[18-23]
 MALDI can be used in the 
analysis of large and/or labile molecules, lipids, peptides, proteins, oligonucleotides, and 
synthetic polymers.
[24-28]
 In this thesis, MALDI was used to characterize the structural 
changes of cryptocyanin protein during the molting and non-molting of snow crab, and 
for determining the ratio of hapten:protein for two synthetic vaccines. 
1.1.2.1 Principle of MALDI 
 In typical MALDI experiments, the sample is mixed with a matrix on a plate. The 
matrix molecules must embed and isolate analytes by co-crystallization. MALDI matrices 
are typically aromatic conjugated molecules that need to be soluble in solvents, and 
compatible with analytes of interest.
[16-21]
 Matrices must be able to transfer or accept 
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protons from non-volatile analytes.
[18-20]
 They must be chemically inert – no reactivity 
with analytes and stable in the high vacuum applied in MALDI-MS.
[16-21]
 The choice of 
matrix depends on the nature of both the laser used in the MALDI instrument and  the 
analyzed sample.
[16-21]
 Sinapinic acid (SA) is commonly used for protein, and α-cyano-4-
hydroxycinnamic acid (α-CHCA) for peptides (see Table 1.1). Typically, MALDI 
employs ultraviolet (UV) lasers such as nitrogen lasers (337 nm) or frequency-tripled and 
quadrupled neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers (355 nm and 
266 nm, respectively).
[18-20]
 Neodymium-doped yttrium lithium fluoride (Nd:YLF) laser 
(349 nm) is also used in some commercial systems.
[18-20]
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Table 2.1 Different types of matrices used in MALDI 
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 The matrix molecules (MH) absorb the laser energy (hѵ), and they become 
excited according to the following mechanism: MH + hѵ → [MH]*. The excited matrix 
molecules [MH]* transfer a proton to the analyte molecule, or they accept a proton 
through a collision with the analyte “M”.  Accordingly, they form a quasimolecular ion, 
for example [M+H]
+
 in the case of an added proton,  [M+Na]
+
 in the case of an added 
sodium ion, or [M-H]
-
 in the case of a removed proton. The formation of [M+H]
+
 and [M-
H]
-
 ions can be controlled by changing the polarity in the ionization chamber of the 
MALDI instrument. MALDI predominantly yields singly charged ions which are referred 
to be as “lucky survivors”,[23] but multiply charged ions ([M+nH]n+) can also be created 
(Figure 1.2).
[18-23] 
The premise of lucky survivor principle is that all ions exist in the 
sample solution, however most ions are removed during MALDI process by 
recombination with counter ions. Then few ions “lucky ones” escape fom this fate, and 
are detected.
[23]
 
 Creation of singly charged ions or multiply charged ions depends on the nature of 
the matrix, the laser intensity and the applied voltage.
[18-23] 
 For example, using SA as a 
matrix with an intact protein, [M+H]
+
 and [M+2H]
2+
 are created.
[18-23] 
 
 MALDI has also been developed to work under atmospheric pressure (AP).
[29,30]
 
Newer sources for atmospheric pressure (AP-MALDI) applications include 
Desorption/Ionization on Silicon (AP-DIOS) and Laser-Induced Acoustic Desorption 
Mass Spectrometry (LIAD-MS). An advantage, of AP-MALDI is that it does not need 
matrix.
[29,30]
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Figure 1.2 Schematic representation of the ionization of the matrix and the analyte in a 
MALDI source.
[18] 
[Reproduced with the permission of the author].  
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1.1.3 Electrospray ionization (ESI) 
 ESI is a soft ionization technique that was developed by John Fenn.
[31]
 In ESI, the 
gas phase-charged ions are created from the macromolecules dissolved in a polar solvent. 
The connection of an ESI source to a quadrupole mass analyzer allowed for the 
development of the first mass spectrometer capable of analyzing proteins with a 
molecular mass up to 40 kDa.
[32,33]
  Furthermore, an ESI source is able to handle flow 
rates up to 1000 μl min-1, which makes it connectable to high pressure liquid 
chromatography (HPLC) system.
[34]
 
1.1.3.1 Principle of ESI 
 In ESI experiments, a sample is dissolved in a polar organic solvent and infused 
into the source through a capillary, under atmospheric pressure. The source of ESI 
instruments consist of two main parts: a spray needle tip and a cone (counter electrode) 
connected to a power supply.
[35-37]
 A high electric potential energy (2-6 kV) is applied at 
the spray needle tip to generate charged droplets in an effect known as the Taylor cone.
[35-
37]
 The droplets migrate with the aid of an electrical field. The droplets are reduced 
continuously in size as solvent evaporates. At a certain limit called the “Rayleigh limit”, 
the droplet is too small and is not able to carry the charges on its surface.
[37]
 Accordingly, 
the droplets explode into small droplets, and then they are dried by warm nitrogen gas.
[35-
37]
 Finally, at the end of the ionization process, single and multi-charged ions are formed 
(Figure 1.3). A typical mass spectrum obtained by ESI-MS of a biomolecule correspond 
usually to a statistical distribution of multiply charged ions produced through protonation 
[M + nH]
n+
, or deprotonation [M - nH]
n-
.
[35-41]
  The formation of [M + nH]
n+
 or [M - nH]
n-
 
can be controlled by changing the polarity of the ESI ion source. During an electrospray 
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experiment, the analyte molecules acquire a charge through proton transfer reactions 
between the electrospray solution and the analyte.
[39-41]
 However, electrochemical and 
photoelectrochemical reactions which take place at the electrode interfaces of the source 
have an influence on the ionization process.
[39-41] 
 In APCI, the ionization of analytes occurs by primaty ions such as O2
·+
 or N2
·+
 
which are formed by corona discharge electrode. APCI is mainly applied for polar 
compounds, and it can be used for less polar samples.
[39]
 However, complete non-polar 
samples cannot be analyzed by either APCI or ESI.
[39-41]
 
 A newer soft ionization technique, namely the APPI, has been developed. It is 
extensively applied for the solid and non-polar compounds. The ionization process takes 
place by interacting of a vaporized sample with photons which are emitted from krypton 
discharge lamp at 10 eV. These photons ionize compounds, which have ionization 
energies below 10 eV.
[39]
  Gases and solvents are not ionized by APPI, however it can be 
applied for polar and non polar molecules.
[39] 
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Figure 1.3 Schematic representation of the production of charged droplets during ESI 
process. MH
+
 is the protonated molecule. 
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1.1.4 Mass analyzers 
 A mass analyzer is the second part of a mass spectrometer, which is used to scan 
and separate charged ions based on their m/z values.
[11,42-49] 
In the mass analyzers, the 
isolation of ions is usually electrically-driven, although traditional analyzers, namely 
magnetic sector instruments, employ a magnetic field that influences ion separation. 
There are four common mass analyzers: quadrupole (Q), quadrupole ion trap (QIT), time 
of flight (TOF) and Fourier transform ion cyclotron resonance (FT-ICR) instruments. In 
this section, I will focus mostly on Q, TOF, and the coupling QTOF analyzers, a type of 
hybrid mass instrument.
[42-56] 
These analyzers vary in size, price, resolution, mass range, 
and the ability to perform MS/MS experiments.
[11,42-49] 
 However, the choices of mass 
analyzer will eventually depend on the mass range, the accuracy of the mass measurement 
and the capacity to distinguish ions with similar m/z values (resolution). Both FT-ICR and 
QIT are capable of doing multiple mass spectrometric experiments (MS
n
), FT-ICR is 
undoubtedly, the most powerful in terms of accurate mass measurements with resolution 
of full width at half maximum (FWHM) 1000,000.
[44]
  
1.1.4.1 Quadrupole analyzer  
 The quadrupole mass analyzer “quadrupole mass filter” was first described by 
Paul Wolfgang in the 1950s, for which he received the Nobel Prize in 1989.
[42-43] 
The 
principle of this analyzer is based on changing ion trajectories by oscillating electric 
fields to separate these ions according to their m/z ratios.
[42-43] 
  A quadrupole analyzer is 
made up of four circular rods, and they are perfectly parallel rods: two of them are 
negatively charged and the other two are positively charged (Figure 1.4).
[42-43] 
 
Simultaneously, direct current potential (DC, or called “U”) and a radiofrequency 
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potential (RF, or called “V”)  are applied between the two pairs of rods, . The operation of 
both DC and RF potentials causes the ions to oscillate according to the equation Φ0=± 
(U±Vcos ωt), where Φ0 is the voltage applied to the rods, ω is the angular frequency, U is 
the DC voltage and V is the RF voltage amplitude.
[6,10,42-43] 
Then, the U, V and ω values 
will be changed to make an ion of a certain m/z value having stable trajectory inside the 
analyzer, and this ion can easily reach the detector “the survived ion is called resonant 
ion”.[6,10,42-43]  For example, the positively charged ions created from the ion source will 
move in the space between the rods. Then, they will be drawn towards the negatively 
charged rods. However, once the polarity of these negative rods is changed, the ion will 
switch their trajectories before striking the rod.
[42-50]
.
 
The remaining ions will possess 
different m/z values and will eventually collide with one of the rods and be lost “these 
ions are called non resonant ions”.[6,10,42-43] The quadrupole mass analyzer presents several 
advantages: excellent transmission efficiency, suitability for GC, liquid chromatography 
(LC) and capillary electrophoresis (CE), low cost, robustness, and easy to use.
[42-43] 
 
However, the mass range of the quadrupole (which is less than 4000 Da), its low 
resolution, and the need to couple more than two quadrupoles to achieve MS/MS 
analysis, are the major limitations of this analyzer.
[42-49,61] 
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Figure 1.4 Schematic representation of a quadrupole mass filter.  
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1.1.4.2 Time of flight (TOF) analyzer  
 The TOF mass analyzer was firstly described by Stephens in 1946, and it is 
considered the simplest mass analyzer.
[50,62]
 The TOF analyzer is compatible with many 
ionization techniques, specifically the pulsed nature of laser in MALDI.
[50,62]
 TOF 
analyzers have been used in different applications for biomolecules such as proteins, 
oligonucleotides, and synthetic polymers.
[24-28]
. 
 Unlike quadrupole and magnetic sector analyzers, the flight of a charged ion 
inside the TOF analyzer to the detector does not require any electrical or magnetic 
fields.
[50,62]
  However, the travelling of charged ions from an ion source to the TOF 
analyzer is simply done under the effect of the applied voltage “Vs”.[62] A charged ion 
travels through a TOF tube, also called, field free area or flight free region, which is 1-2 
m in length.
[62, 63]
  
 Ions travel from the ion source in bundles by laser desorption.
[62-64]
 Then, they are 
accelerated to the TOF tube by applying a voltage between an electrode and an extraction 
grid (see Figure 1.5). All accelerated ions gain the same kinetic energy “Ec” = 1/2mv
2
 = 
qVs (m is mass of the ion, v = velocity of the ion, q is charge of the ion, Vs = the applied 
voltage at the acceleration region). In addition, the travelled ion has the charge “q” = Ze (Z 
= charge number, e = elementary charge) and mass “m”.[62-64] So: 
Ec = 1/2mv
2
 = qVs= ZeVs 
v = (2 Ze Vs/m)
1/2 
Thus, the ion travels from the accelerated region of the ion source to TOF tube by a 
velocity, v = (2 Ze Vs/m)
1/2
.
[62-64]
 Then, the ion moves in straight line inside the flight free 
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region at constant velocity “v” to the detector. The time required for travelling the field-
free region with a length L before reaching the detector is given by t = L/v.
[62-64]
 
Replacing v by its value from the previous equation gives: 
t = L/ (2 Ze Vs/m)
1/2 
t
2
 = m/z (L
2
/2e Vs)
 
 Thus, the separated ions will be measured based on their m/z values, since the 
other factors L, Vs and e are constant.
[62-64] 
 Unlike with quadrupole or magnetic sector 
analyzers, in a TOF instrument, all formed ions will eventually reach the detector.
[62-71] 
 The linear mode of a conventional TOF analyzer (Figure 1.5A) has been refined 
because its resolving power is limited.  The linear mode has been modified into a reflector 
mode, in which an electrostatic ion mirror “reflectron”, is incorporated to increase the 
resolving poweras shown in Figure 1.5B.
[65] 
 Currently, all modern MALDI-TOF-MS operate with delayed pulsed extraction 
(also known as time-lag focusing).
[51]
 Delayed extraction is amethod used in TOF to 
increase the resolution of TOF analyzer by reducing the kinetic energy of some ions 
which have the same m/z ratio. A voltage pulse is applied to detect the ions outside the 
source with typically the same m/z ratio.
[51]
 In contrast to contionous extraction used in 
conventional instruments, delayed extraction increases the mass resolution with high 
sensitivity.
[51]
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Figure 1.5 Schematic representation of a conventional TOF analyzer (A) and a reflectron-
type TOF (B). 
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1.1.4.3. Hybrid quadrupole/time-of-flight (QTOF) mass spectrometer  
 Hybrid mass spectrometers consist of different types of mass analyzers. 
Accordingly, a QTOF instrument consists of two different types of analyzer: three 
quadrupole analyzers and one time of flight analyzer (Figure 1.6).
[51-71]
 The purpose of 
combining two or more different analyzers is to increase the mass resolution, and to 
provide high-quality, informative, simple, one-stage MS and tandem MS/MS spectra. 
  Despite the coupling of the TOF analyzer with MALDI source is common 
because the TOF system works on a pulsed process (pulsed nature of the laser).
[51-65]
 
However the coupling of TOF analyzer with an ESI or any other API sources is difficult 
because these sources produce a continuous ion beam.
[51-71]
 Thus, the TOF was not 
suitable to be coupled with ESI until the development of the orthogonal injection system 
(also called orthogonal acceleration system “oa system”). In the “oa” system, the ion is 
accelerated with a direction which is perpendicular to its initial direction, and then the 
continuous ion beam will be transformed into a pulsed process.
[51-71]
 It was reported that 
the properties of ESI combined to orthogonal TOF “reflector TOF” have shown great 
potential.
[59,66] 
ESI-QqTOF hybrid instruments use lower internal energies for the 
fragmentation of molecular ions. Thus, the spectra of ESI-QqTOF hybrid instruments are 
relatively easy to interpret. Additionally, ESI-QqTOF shows a resolving power of 10,000 
FWHM. Another advantage of LC-ESI-QTOF mass spectrometry is its adaptability to 
protein identification and sequencing.
[52-66]
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Figure 1.6 Schematic representation of QTOF instrument (QSTAR hybrid QqTOF). 
QTOF consists of three quadrupole Q0 is the first quadrupole, Q1 is the second 
quadrupole, and Q2 is the third quadrupole. Ar, argon; MCP, microchannel plate;RF, 
radiofrequency. [Reproduced with the permission from the publisher of Ref. 11] 
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1.1.5 Tandem mass spectrometry  
 Tandem mass spectrometry is often abbreviated as MS/MS or MS
n
, typically 
consists of at least two analyzers coupled together.
[66-71]
 The first analyzer is used for the 
selection of a precursor ion (parent ion which is desired to be fragmented). The second 
analyzer is used for the scanning of product ions (fragments ions of the precursor ion). 
The precursor ion fragmentation can be done by using a neutral gas such as argon or 
helium in the case of collision induced dissociation (CID), by collision with the collision 
cell surface in the case of surface induced dissociation (SID), by using electrons in the 
case of electron capture dissociation (ECD) or by laser in infrared multiphoton 
dissociation (IRMPD), see Figure 1.7. There are two different types of tandem mass 
spectrometry; tandem in space and tandem in time.
[66-73]
 
1.1. 5.1 Tandem in space and tandem in time 
 With tandem in space, the mass spectrometer consists of more than one analyzer 
and a collision cell. The first mass analyzer is used to select an ion “precursor ion” for 
analysis. The precursor ion is then fragmented inside the collision cell to produce the 
product ions. Then, the second analyzer will analyze the product ions.
[71-73]
 
With tandem in time, a selected precursor ion is trapped for a specific time in the 
first analyzer. The product ions are formed inside the first analyzer. Then, the second 
analyzer will scan for product ions. This type of tandem MS is more common in QIT, the 
FTICR, and the Orbitrap instruments.
[71] 
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Figure 1.7 Schematic of tandem mass spectrometry. CID, collision induced dissociation; 
SID, surface induced dissociation; ECD, electron capture dissociation; IRMPD, infrared 
multiphoton dissociation. 
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1.1.6 Protein mass spectrometry 
 Mass spectrometry of proteins is a way for characterizing and sequencing a 
protein through two common approaches: a top down approach and a bottom up 
approach.
[1,74]
 A single stage MALDI, or a de-convolution process of ESI are used for 
determining the protein molecular mass in its intact form.
[1,74,75] 
In the single stage 
MALDI of an intact protein, two major ions [M+H]
+
 and [M+2H]
2+
 are usually 
generated.
[1,74,75] 
Then, the protein molecular mass is measured by removing a proton 
from the [M+H]
+
 ion. Thus, in the de-convolution process of ESI, the MS software 
transforms group of peak ions based on their intensities and charges into a single ion 
peak, which symbolizes the protein molecular mass.
[1,74,75]
 Single stage MALDI is 
preferred due to its low salt tolerance and its lower fragment spectrum.
[1,74,75]
 
 Top down proteomics and bottom up proteomics are powerful methods for the 
identification of proteins based on mass spectrometric analysis and database homology 
searches.
[1,76-81] 
The first step in both approaches involves the extraction of a protein by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels, LC 
separation, immunopurification or two dimensional (2-D) gels.
[1,76-81] 
 The principle of 
both approaches is similar, but the form in which the protein is introduced to the mass 
spectrometer is different in the two approaches.
[1,76-81] 
 In the top down approach, the 
isolated protein is introduced to an ESI mass spectrometer in its intact form.
[76-80] 
 This 
protein will then be degraded into product ions during the MS/MS gas phase 
fragmentation.
[76-80]
 
 In bottom up proteomics, proteolytic digestion of the protein must be done prior to 
introducing the protein into the mass spectrometer.
[1,81,82]
 The preolytic digestion is done 
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by enzymes which cleave at specific sites on the protein (e.g. trypsin cleaves at the 
carboxylic end of lysine and arginine or Gluc V8 cleaves at the carboxylic end of 
glutamic acid and aspartic acid).
[1,81-85]
 This approach consists of two major stages: 
peptide mass fingerprinting (PMF) and tandem MS/MS ions searches.
[1,81-85] 
 PMF and MS/MS ion searches are performed individually by processing the MS 
and MS/MS spectra, respectively, into a peak list. By introducing the peak list into a MS 
database, a report will be generated, which will provide the similarities between your 
protein and other proteins recorded in the database. The high similarities (matching parts) 
are represented by high scores.  
 In PMF and MS/MS ion searches, the identity of the original protein is determined 
by comparing the peptide mass spectra with theoretical peptide masses calculated from a 
proteomic or genomic database.
[1,81-85]
 Both PMF and MS/MS ion searches are 
complementary to each other.
[1,81-85]
 However, PMF results include unmatched masses 
from MS spectra due to post translational modifications causing mass shifts, partial 
proteolysis or non-specific cleavages.
[1,81-85]
  PMF does not work for identifying mutant 
forms of a protein. For that reason, MS/MS data are necessary for identifying peptide 
sequences and for avoiding false positive results. Figure 1.8 illustrates the major steps of 
bottom up proteomics approach, which also referred to be as shotgun proteomics. 
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Figure 1.8 Workflow in bottom up proteomics. Protein is extracted from a mixture, 
separated, digested, and analyzed by tandem mass spectrometry. The PMF and MS/MS 
ions search is done through the Mascot protein database. SDS, sodium dodecyl sulfate; 
2D, 2 dimensional; PMF, peptide mass fingerprint; MS, mass spectrometry; MS/MS, 
tandem mass spectrometry.  
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1.1.7 Gas phase fragmentation of proteins and carbohydrates 
Gas phase ions are formed in the ionization source. It was observed that during the 
ionization process, the energy gained by an ionized molecule plays a role in the formation 
of in-source fragment ions. Then, the precursor ions are fragmented into product ions via 
MS/MS. In the case of a protein, the product ions are amino acid fragments. Roepstorff 
and Fohlman proposed the conventional nomenclature of amino acid fragments, which 
was subsequently modified by Johnson in 1987.
[86, 87]
 Figure 1.9 shows the nomenclature 
of the peptide fragments, which are generated by CID-MS/MS. There are two types of the 
peptide fragments: fragments of amino terminus (a, b, c) and fragments of carboxyl 
terminus (x, y, z). Sometimes, internal fragment with  a single side chain formed by the 
combination of a- and y- fragments is called an immonium ion.
[86,87]
 However, my focus 
will be on y- and b- fragments because these fragments represent a complete amino acid 
or a complete peptide.
[86,87]
  
De novo peptide sequencing using mass spectrometry can be achieved by the 
aforementioned bottom up proteomics approach, in which the databases have been used 
for calculating the y- and b- ions via MS/MS ion search. Since not all y- and b- values are 
shown on a spectrum, calculating y- and b- values manually becomes a big challenge.
[1,81-
85]
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Figure 1.9 Peptide fragmentation nomenclature. This figure is adapted from the Ref. [86]. 
 
 
  
 
 
 
 
 
 
 28 
 
 In 1988, Domon and Costello reported the carbohydrate fragmentation 
nomenclature (Figure 1.10).
[89]
 The idea of carbohydrate fragmentation nomenclature is 
similar to that of protein nomenclature. According to Domon and Costello, there are two 
types of carbohydrate fragments: X, Y, Z fragments from the reducing end and A, B, C 
fragments from the non-reducing end (X or A fragments come from the fission through 
the oxonium ion ring).
[89]
  
 In Figure 1.10, R stands for a non-carbohydrate group (protein or lipid), which is 
bound to the carbohydrate part through a spacer (linker). So, a resulting spectrum should 
contain fragments of the carbohydrate part, the non-carbohydrate part and/or the spacer 
linked to either carbohydrate moiety or R.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
 
 
 
 
 
 
 
 
 
Figure 1.10 Carbohydrate fragmentation nomenclature. R, reducing end. [Reproduced 
with the permission from the publisher of the Ref. 84] 
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1.2 Snow crab (Chionoecetes opilio) 
 Snow crab (Chionoecetes opilio) is a Brachyuran crab of the family Majidae.
[89]
 
The fishery of this species occupies a large area of Newfoundland’s southeast coast since 
it is found from the Gulf of Marine to West Greenland. It is the most valuable economic 
fishery on the Grand Bank of Newfoundland’s southeast coast.[89]  
 Snow crabs are invertebrates and have immune system that lack immunological 
specificity.
[90] 
They lack  memory cells and lymphocytes, and accordingly the immune 
system does not involve antigen-antibody reactions.
[90] 
Instead, it relies mainly on 
antimicrobial proteins.
[90] 
It was reported that there are different antimicrobial proteins 
found in different species of crabs. These proteins are secreted directly into the blue blood 
of the crabs (crab hemolymph).
[90] 
Proline peptide was the first antimicrobial peptide 
characterized in shore crab (Carcinus maenas).
[90,91] 
Both a lectin and callenactin peptide 
have antimicrobial activity in blue crab (Callinectes sapidus).
[92,93] 
 Mud crabs (Scylla 
serrata) have two antimicrobial proteins in its hemolymph: scygonadin of 43 kDa and a 
lectin of 4 kDa, which is called scyllin.
[94]
 Additionally, lectin is bound non-covalently to 
sialic acid to act as an antimicrobial complex in Indian horseshoe crab (Carcinoscorpus 
rotunda).
[94,95]
 Furthermore, a complex of crustin protein with characteristic four disulfide 
core- containing whey acidic protein (WAP) domain is the key player in the immune 
system of spider crabs (Hyas araneus).
[96,97]
 In this thesis, I have focused on an 
antimicrobial protein from snow crab (Chionoecetes opilio), which is called cryptocyanin. 
 Snow crabs are crustaceans which undergo an ecdysis (molting) process, which 
allows the snow crab to grow.
[98] 
It involves shedding off the exoskeleton, and for a short 
time afterward the crab is unable to move until it regains muscle control and the new 
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exoskeleton hardens.
[98] 
At this point the crab will begin eating the old exoskeleton which 
helps to recycle the calcium carbonate and other minerals necessary for the new 
exoskeleton’s health and rigidity.[98] Because crabs are vulnerable during this time, they 
tend to bury underground in the ocean’s muddy floor for protection, insulation, and 
darkness, which is necessary to allow the molting hormone (MH) to be secreted so that 
the shedding process can begin.
[98-101]  
Molting is an important sign of growth as the snow 
crab matures and gets ready to reproduce.
[98] 
During molting, the crab is more susceptible 
to microbial infection as the new exoskeleton becomes soft.
[98-101] 
Hence, the crab 
cryptocyanin is elevated five-fold to adapt its function as anti-microbial protein.
[98-101]
 
1.2.1 Cryptocyanin  
 Cryptocyanin is a hexametric protein which exists in different crab species 
including Dungeness crab (Metacarcinus magister) and blue crab (Portunus 
pelagicus).
[99-104] 
Cryptocyanin and hemocyanin are the most abundant proteins found in 
the snow crab hemolymph.
[99-104] 
They are synthesized in the hepatopancreas and are 
directly secreted in the crab hemolymph.
[99-104] 
Both proteins are similar in size, sequence 
and structure. 
[99-104] 
The hemocyanin structure has copper sites, and cavities to hold 
oxygen.
[99-104] Thus, it acts as a respiratory protein “oxygen transporter”.[99-104] Unlike 
hemocyanin, cryptocyanin is a copper free protein, and it is a non-respiratory protein. 
However, cryptocyanin is expressed from the same gene of hemocyanin, which is called 
the hemocyanin gene duplication or fusion.
[99-104]
 
 Cryptocyanin expression is controlled by a hormone called molting inhibiting 
hormone (MIH).
[99-104] 
MIH is secreted from an endocrine organ called the X organ-sinus 
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gland system (XO-SG), which is found in the crab eyestalk. Consequently, ablation of 
eyestalks leads to the suppression of cryptocyanin.
[99-104] 
1.2.2 Cryptocyanin functions   
 The snow crab fishing season takes place after the crabs have molted and have 
new shells. The ability to predict the proportion of adolescent crabs that will molt and 
appear as soft-shelled individuals will allow industry to avoid fishing in areas where high 
incidences of soft crabs are likely. Cryptocyanin can be used as a predictor tool for the 
fishing season since its concentration is elevated five times during the premolt stage. 
 More interestingly, during the non-molting stage, crab cryptocyanin has many 
functions. It works as a carrier protein for steroids, hormones and fatty acids.
[105] 
 This 
function is similar to serum albumin which constitutes 50% of human serum protein.
[105] 
Additionally, it has a putative osmolyte role.
[105] 
  Moreover, cryptocyanin has divalent 
cation binding sites for Ca
2+
 and Mg
2+
 ions. Besides the non-molting functions, 
cryptocyanin carries the Ca
2+ 
ions from the old exoskeleton to the hemolymph, preparing 
for the molting process.
[105]
 Somewhere Ca
2+ 
ions have been stored on the loading sites of 
cryprocyanin until their use for hardening the new exoskeleton during the molting 
process. At the time of ecdysis, cryptocyanin moves from the hemolymph in an elongated 
epidermal cell to the new shell in order to deliver the Ca
2+ 
ions. At such time, 
cryptocyanin levels are elevated to achieve its immune function because the crab’s new 
shell is soft, and the snow crab is more susceptible to microbial infection.
[105] 
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1.3 Vaccines 
 A vaccine is a substance used to confer protection by stimulating the immune 
system to secrete antibodies against diseases.
[106,107]
 In 1796, Edward Jenner discovered 
that the human inoculation with cowpox was able to protect against smallpox 
infection.
[106,107]
 Since then, different vaccines were developed to prevent infectious 
disease.
[106,107]
 There are different forms of vaccines: attenuated vaccines, inactivated 
vaccines, toxoid vaccines, subunit vaccines, DNA vaccines, recombinant vector vaccines 
and conjugate vaccines.
[108]
 
1.3.1 Live, attenuated and inactivated vaccines 
 Live, attenuated vaccines confer protection by natural infection with a “living 
microbe” that has been manipulated to suppress the virulent effect.[108,109] Live attenuated 
vaccines provoke a strong immune response but can also cause disease in patients with a 
flagging immune system such as those with HIV infection or receiving 
chemotherapy.
[108,109]
 Another drawback of this vaccine, is that it is not specific for many 
bacteria because they have different species or genes. Additionally it needs to be 
refrigerated to stay potent.  Examples include vaccines against measles, cholera, mumps 
and chickenpox.
[108,109]
 
 An inactivated vaccine is created to avoid the drawbacks of the attenuated one. 
This type is produced after killing the microbe by chemicals like formaldehyde, by 
irradiating or through heat. An inactivated vaccine cannot cause the disease. However, it 
tends to elicit a weak immune response.
[108,109]
 Example includes a vaccine against 
hepatitis A.
[108,109] 
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1.3.2 Toxoid and subunit vaccines 
 An antigenic part of a microbe or its secreted toxin can cause infection. 
Accordingly, scientists use these parts of microbes for designing vaccines. When 
preparing vaccines against bacterial toxins, the toxin is treated by formalin to make it 
harmless, called the “detoxified form”. These “detoxified” toxins are used as toxoid 
vaccines.
[108,109]
 When the toxoid vaccine is administrated, the immune system generates  
a strong immune response to the neutralized toxin, and accordingly it produces enough 
antibodies to block the toxin sites. Examples of toxoid vaccines include those against 
diphtheria and tetanus.
[108,109]
 
 As an alternative, parts of the microbe “different epitopes” are used to synthesize 
the subunit vaccines. The drawback with such type of vaccine, is its non-
specificity.
[108,109]
 Accordingly, one vaccine needs 1-20 epitopes to be more specific 
[108,109]
 Important epitopes can be picked up after chemical degradation of the microbe, so 
it is time consuming process.
[108,109]
 These epitopes can be manufactured using 
recombinant DNA technology. The hepatitis B vaccine is an example for this type of 
vaccine.
[108,109]
 
1.3.3 DNA and recombinant vector vaccines 
 DNA vaccines are prepared by making use of microbial genes that encode vital 
antigens to make a vaccine against the microbe. DNA vaccines, containing these genes, 
can be picked up by competent host cells after administration by using a syringe.
[108-111]
 
The host cell works as a factory to translate these genes and to produce antigens which 
stimulate a strong immune response. Examples of DNA vaccines include those used for 
herpes and influenza vaccines.
[108-111]
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 Since, not all host cells are capable  picking up the naked DNA vaccine. Scientists 
have tried to increase the efficiency of the naked DNA vaccine by making a coat around 
the genes using gold molecules, to facilitate its uptake by the host cells.
[108-111]
 
Accordingly, recombinant vector vaccines have been developed in which vectors (viruses 
or bacteria, which work as gene carriers) are used for introducing the microbial genes to 
the host cells.
[108-111]
 
1.3.4 Conjugate vaccines 
 Gram negative bacteria cell walls are coated with lipopolysaccharides 
(LPS).
[112,113]
 LPS consists of three main parts: an external part called the O-antigen, 
which is composed of repeats of identical sugar oligosaccharide units, and an internal 
core which is covalently linked to the third part, “lipid A” (Figure 1.11).[112,113] Lipid A 
represents the toxic part of LPS, and it consists of a β-D-(1→6) glucosamine (GlcN) 
disaccharide in which O-3, O-3’, O-4’, C2-N and C2-N’are acylated with different C:12 
and C:14 fatty acids.
[112,113]
 The carbohydrate part of the lipid A or the O-antigen part can 
be conjugated with biomolecules such as proteins or dendrimers (elegant branched 
molecules consist of cascade molecules) to create a glycoconjugate vaccine.
[112-115] 
A carbohydrate antigen neoglycoconjugate vaccine is composed of the 
carbohydrate part called a “hapten” linked by a spacer to a biomolecule (which is usually 
a protein), see Figure 1.12. The synthesis of efficient glycoconjugate vaccines depends 
on many factors, and their efficacy relies on the saccharide size, the average number of 
saccharide chains per conjugate molecule, the nature of the carrier and the distance 
between the saccharide and the protein in the formed glycoconjugate.
[116-119]
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Figure 1.11 Lipopolysaccharide of gram negative bacterial cell wall. P, Phosphorous 
group 
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Figure 1.12 Composition of the glycoconjugate vaccine. 
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 It is worthy to mention that antigenic carbohydrate-protein vaccines are not 
limited to fighting bacteria, as they can be developed as anticancer drugs by conjugation 
of a tumor associated carbohydrate antigen (TACA) to a carrier protein.
[120]
 The first 
carbohydrate-protein vaccine was reported by Landsteiner’s group,[121,122] and later, it was 
discovered that they can induce strong antibody reaction.
[123]  
Different methods have been used for the synthesis of carbohydrate antigen-
protein neoglycoconjugates. One of these methods consisted of the use of squaric acid 
chemistry for the single-point attachment of carbohydrates to proteins.
[123-126] 
Tietze et al. 
used squaric acid diethyl esters for  conjugation.
[124] 
It has also been reported that squaric 
acid dimethyl esters,
[127,128] 
as well as didecyl squarate
[129]
 can be used for the single point 
attachment of carbohydrates to proteins. In addition, Kamath et al. used squaric acid 
amide ethyl esters for the conjugation of oligosacharrides to protein and monitored the 
conjugation using MALDI-TOF-MS.
[130] 
 
More recently, the group of Kováč utilized squaric acid chemistry to conjugate 
different carbohydrate antigens to a protein carrier.
[131-134] 
They used this strategy to 
conjugate the synthetic tetrasaccharide side chain of the Bacillus anthracis exosporium to 
bovine serum albumin (BSA) protein.
[133]
 Michael addition is a conjugation addition 
reaction, which has been used for targeting the sulfhydryl group of the cysteine residues, 
and the ɛ- amino groups of lysine residues.[135-138] In this study, Michael addition was 
used to target the free sulfhydryl group of cysteine 34 (Cys 34) on BSA. BSA is rich in 
potential glycation sites because it contains 60 lysine residues and 35 cysteine residues, 
34 of which form 17 disulfide groups, leaving one free sulfhydryl group on the Cys 
34.
[139-140]
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 In essence, the carrier protein used in the glycoconjugate vaccine synthesis is very 
important, since this part is responsible for production of the memory cells which confers 
protection.
[141]
 Recently, Roy’s group had provided evidence for the role of the carrier 
protein.
[142] 
The carrier protein had been replaced with repetitively branched molecules 
called dendrimers. Conversely, dendrimers do not elicit the memory B cells, although 
they provoke plasma B cells to secrete enough antibodies.
[142]
 
1.3.5 Principle of glycoprotein vaccines 
 The major role of glycoprotein vaccine is to confer protection through the 
production of memory cells. In case of infection, the immune system produces antibodies 
to kill the infected cells. However the memory pool is depleted and the memory cells are 
not secreted Figure 1.13.
[141]
 Figure 1.14 shows the molecular mechanisms of the 
generation of immune responses against protein-polysaccharide conjugate vaccines.
[141] 
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Figure 1.13 Generation of the immune responses against the infection.
[141]
 BCR, B cell 
receptor; IgG2, immunpglobinG2; IgM, immunoglobin M. [Reproduced with the 
permission from the publisher of Ref. 141]. 
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Figure 1.14 Generation of the immune responses against oligosaccharide antigen-carrier 
protein conjugate vaccines 
[141]
 BCR, B cell receptor; MHC, Major histocompatibility 
protein; CD, cluster designation; TCR, T cell receptor; IgG1, imuunoglobin1; IgG3, 
imuunoglobin3.  [Reproduced with the permission from the publisher of Ref. 141].  
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1.3.6 Thomsen–Friedenreich antigen (TF) 
 Thomsen–Friedenreich antigen (TF) is a TACA recognized by major 
histocompatibility protein class I.
[142-147]
 TF is a disaccharide (β-galactose and α-
galactoseamine) bound to the hydroxyl group of threonine and serine residues on the core 
of mucin protein (Figure 1.15).
[142-147]
 It helps different cancers such as breast, colon, 
prostate or bladder to metastasize, and it causes aberrant O- glycosylation of the mucin 
protein. In case of cancer, 50% of mucin O-sites gain O-glycosylation by TF and TN (N-
acetylglucoseamine) antigens.
[142-147]
 Additionally, sialic acid glycoproteins are 
overexpressed by cancer cells. So, in case of cancer, sialyl TF and silayl TN have been 
formed, causing aberrant glycosylation.
[142-147] 
 Several studies were reported for a drug design against the aforementioned 
antigen “TF”. Monoclonal antibodies had been produced from mouse such as JAA-F11 
(IgG3) and C5 (IgM). More recently, Hoffmann-Röder et al. prepared several synthetic 
antitumor vaccines composed of BSA conjugates of mucin 1 (MUC1) glycopeptides with 
the TF (TF -MUC1-BSA conjugate) and a fluorine-substituted analogue (difluoro- TF -
MUC1-BSA conjugate).
[148,149]
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Figure 1.15 Typical structure of representative TF antigen bound to the hydroxyl group 
of serine (Ser) or threonine (Thr) on mucin glycoprotein accumulated on the cancer cell. 
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1.3.7 Strategy for characterization of glycoconjugate vaccines using MS 
  Initially, application of MALDI-TOF-MS to the different hapten-BSA 
glycoconjugate vaccines allowed us to determine the hapten-to-BSA ratios. Then the 
glycoconjugate vaccine samples were digested and analyzed by MALDI-TOF/TOF-
MS/MS and LC-ESI-QqTOF-MS/MS for the determination of glycation sites.  The 
digestion is done by two different enzymes; trypsin which will not be able to digest or 
react with the glycated lysine residues of the protein and the other enzyme is GluC V8 
endoproteinase which is known to digest proteins at C-terminus of the aspartic acid and 
glutamic acid residues. Finally the MS/MS spectra are submitted to Mascot library to get 
the matched and non-matched peptides. 
1.3.8 Molecular mass and carbohydrate-to-protein ratio determination 
The purpose of determining the molecular mass and the carbohydrate-to-protein 
ratio of a carbohydrate-protein neoglycoconjugate is to define the number of 
carbohydrates that are incorporated in the protein carrier, as a result of conjugation. Two 
main methods are currently used for the molecular mass determination of carbohydrate-
protein glycoconjugates: MALDI-TOF-MS
[150,151] 
and surface enhanced laser desorption 
ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
[131-133,152-154]
. 
 Both of these methods allow the carbohydrate-to-protein ratio of the 
neoglycoconjugates to be determined by comparing the molecular mass of the protein 
before and after the conjugation to that of the neoglycoconjugate.  
1.3.9 Glycation sites determination 
The glycation sites determination of carbohydrate-protein neoglycoconjugates is 
usually carried out by first digesting the neoglycoconjugate using a protease, such as 
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trypsin or GluC V8 endoproteinsase, followed by MALDI-TOF-MS/MS or LC-
MS/MS.
[83-85,155]
 
It has to be noted that during the tandem mass spectrometry analysis of the 
glycoconjugate digests, the identification of the glycated peptides are confirmed by the 
presence of diagnostic product ions of the carbohydrate in the mass spectrum. In addition, 
the tandem mass spectrometry analysis also reveals the sequence of the peptide through 
diagnostic product ions of the peptide moiety of the glycated peptide. The combined 
information allows the unambiguous characterization of the carbohydrate-peptide and 
glycation site identification. It has to be noted that during tandem mass spectrometry 
analyses of the glycated peptides, the product ions corresponding to the fragmentation of 
the peptide portion are identified using the nomenclature established by Roepstorff et al. 
and lately is modified by Johnson and coworkers,
[86,87] 
and the product ions resulting from 
the fragmentation of the carbohydrate moiety are assigned using the nomenclature 
introduced by Domon and Costello, as: A, B, C, X, Y and Z.
[88]
 
1.4 Research objectives 
 The objectives of this work are to use the mass spectrometric bottom-up 
proteomics approach for characterizing cryptocyanin protein in snow crab. Additionally, a 
proteomics strategy is used for mapping the glycation sites of an anti-cancer Thomsen–
Friedenreich vaccine. 
1.5 Hypotheses  
 MALDI-CID-MS/MS and ESI-CID-MS/MS can be used as effective proteomic 
approaches to sequence cryptocyanin and for glycation site mapping of the anti-tumor TF 
neoglycoconjugate vaccine. Gel electrophoresis is not an accurate tool for determining the 
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molecular mass of unknown proteins such as my protein of interest “cryptocyanin”. I 
hypothesize that single stage MALDI will prove to be an accurate means of measuring the 
molecular mass of protein, particularly cryptocyanin. In addition, cryptocyanin protein of 
snow crab in the non-molting stage is expected to change its structure to adapt its function 
as a key player in hardening the new shell of the snow crab, and its role as antimicrobial 
protein. I hypothesize that these changes can be identified by single stage MALDI 
technique.  
 In the second part of this work, I further hypothesised that Cys 34 residue on BSA 
is more reactive than the lysine residues, accordingly two ratios (one with high glycation 
sites and the other with low glycation sites) are prepared using Michael addition, which is 
specific for targeting the cysteine and lysine residues.
[139-140]
  
1.6 Summary 
 Bottom up proteomics is an exceptional approach that uses MS/MS for protein 
sequencing. In this thesis, examples of the uses of MS/MS for different biomolecules will 
be presented. Two key examples include: MALDI and MS/MS for the determination of 
changes in snow crab cryptocyanin protein, and ESI-QqTOF MS/MS is used for mapping 
of the glycation sites of the anti-tumor TF neoglycoconjugate vaccine, as well as the 
glycation of the free sulfhydryl group of Cys 34 of BSA. 
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2.1 Introduction 
The harvesting of snow crab is one of the largest and commercially important 
fisheries on the Grand Bank of Newfoundland’s southeast coast in the northwest 
Atlantic.
[1] 
It is one of the most valuable crustacean invertebrate catches for commercial 
fishers. It is well known that the immune system of crabs is very simple and it lacks 
immunological specificity since it does not contain lymphocytes or memory cells; instead, 
the immune system relies on antimicrobial peptides or proteins.
[2]
  
  During its molting period, the crab reabsorbs some of the calcium carbonate 
from the old exoskeleton, and secretes enzymes to separate the old shell from the 
underlying skin (or epidermis) which secretes a new, soft, paper-like shell beneath the old 
one.
[2-4]
 During this molting phase the snow crabs are susceptible to infection as their 
outer shells became soft.
[4,5]  
It has been suggested that the high level of cryptocyanin protein in the crab 
molting stage, reflects its function adaptability as an antimicrobial protein used to kill 
microbes.
[2-4]
 In consequence,
 
cryptocyanin is considered a significant antifungal, 
antimicrobial and antiviral protein which is present in the hemolymph.  
Both cryptocyanin and hemocyanin proteins are synthesized in specific cells of 
the crab hepatopancreas and are secreted directly in the hemolymph.
.[2-4]
 In addition, 
jointly hemocyanin and cryptocyanin constitute the most abundant proteins of the 
crustacean hemolymph. Unlike hemocyanin which contains copper, cryptocyanin is a 
copper free protein which does not bind to the oxygen. Consequently, cryptocyanin has 
been described as a non-respiratory protein.
[3]
 Nevertheless, cryptocyanin resembles 
hemocyanin in its sequence, structure, size and it is produced from the hemocyanin 
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duplication gene.
[3]
 Besides, cryptocyanin is responsible for profound physiological 
functions such as ion regulation and cardiovascular functions.
[3]  
The expression of cryptocyanin has been reported to be controlled by the 
crustacean molt inhibiting hormone (MIH) which is synthesized and excreted from the 
important endocrine organ in the optic ganglia of the crustacean’s eyestalk called the X 
organ-sinus gland system (XO-SG) eyestalk.
[3-11]
 
In this manuscript, we report the measurements of the level of cryptocyanin 
during the molting and non-molting stages and we demonstrate that there are indeed 
structural differences between the molting and non-molting cryptocyanin proteins of the 
crustacean snow crab (Chionoecetes opilio) hemolymph.  
2.2 Material and methods 
2.2.1 Chemicals and reagents  
Acetonitrile (ACN) and methanol were purchased from Anachemia (Lachine, QC, 
Canada). Glacial acetic acid and ammonium bicarbonate (NH4HCO3) and were bought 
from Sigma-Aldrich (Oakville, ON, Canada). Iodoacetamide and Dithiotreitol (DTT) and 
Bovine Serum Albumin (BSA) were bought form Sigma Aldrich (Saint Louis, MO, 
USA).  All SDS-PAGE chemicals and reagents were purchased from Bio-Rad 
(Mississauga, ON, Canada).  Zip Tips C18 were bought from Millipore (Bedford, MA, 
USA).  
2.2.2 Sample preparation 
Juvenile and adult snow crabs were collected from Grand Bank of Newfoundland 
and kept in running seawater at ambient temperature and salinity at the Department of 
Fisheries and Oceans Canada (DFO). 
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2.2.3 Extraction of snow crab hemolymph 
Using a sterile syringe, 20-35 ml of hemolymph (blue blood) were withdrawn and 
collected into sterile propylene centrifuge tube cooled with ice to decrease the rate of 
blood clotting. The blood was centrifuged immediately at 730 rpm for 10-15 minutes and 
the supernatant (plasma) is recollected in another sterile tube and stored frozen at -80
o
 C 
for 24 hours. The frozen sample was lyophilized for three days and kept in 4
o 
C for 
further use.
[12]
 
2.2.4 Protein precipitation 
The freeze-dried lyophilized plasma sample was dissolved in distilled water 
(10ml) and the protein was precipitated using 25 ml of a 50% polyethylene glycol 4000 
(PEG 4000) solution, and then centrifuged at 700 rpm for 10 minutes. The supernatant 
was further treated gradually with 50% PEG 4000 until a final concentration of 16% PEG 
4000 was obtained. The protein precipitate was kept at 4
o 
C for further used.
[12] 
2.2.5 Electrophoresis  
The protein precipitate was diluted with SDS buffer (50 mg protein sample + 500 
μl SDS buffer), and then boiled for 3 minutes. The loading buffer was prepared at pH 6.8 
Tris Buffer (65ml glycerol + 6.5g SDS + sodium azide 0.1 g + 3.94g Tris, dissolved in 
500 ml distilled H2O). Ten microliters (per well) of the diluted sample was run on a 8% 
polyacrylamide gel at 100 volts for 60 minutes. The gel was stained and fixed using 
Coomassie Blue stain in 10% glacial acetic acid and followed destaining in 50% 
methanol solution for 45 minutes.  
In order to isolate the intact protein, the protein band corresponding to 
cryptocyanin was excised from the gel, cut into 1 mm-cubes and then was transferred in 
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0.5 ml microfuge tubes. The gel pieces were washed with water and a solution of 100 µl 
50 mM NH4HCO3/ 50% a ACN 1+1 (v/v) for 15 minutes. Then, all remaining liquid was 
removed and 100 µl excess acetonitrile was added and the gel pieces were shrunk and 
stuck together. Acetonitrile was removed and the gel pieces were rehydrated by 25µl of 
50 mM NH4HCO3. The intact protein was extracted with an extraction buffer of 50 µl of 
50% acetonitrile containing 0.1% trifluoroacetic acid (TFA). The extract was dialyzed in 
a dialysis tube with cut off of 35 kDa. Single-step desalting, concentration, and 
purification before MALDI measurements was performed using Zip Tip C18.
[13]
 
2.2.6 Confirmation of the identity of the cryptocyanin gel band  
Two methods were used to confirm the identity of the cryptocyanin gel band. The 
first method relied on the detection of the presence or absence of copper metal, measured 
by atomic absorption spectrometry, on the proteins extracted from the 75 kDa gel band.
[4]
 
The second method was based on the ablation of the eyestalk during the molting process 
of three juvenile crabs following collections of hemolymph samples at day 7, 14 and 21.
[4]
 
Similarly, like the previous steps, the hemolymph proteins were run on the gel with the 
same percentage of polyacrylamide, which was 8%.
[12]
 
2.2.7 Tryptic Digestion of Cryptocyanin 
The identification and sequencing of cryptocyanin peptides was achieved by 
tryptic in-gel digestion of cryptocyanin. The excised gel bands were dehydrated with 50 
μl acetonitrile and rehydrated with the same volume of 50 mM of NH4HCO3. The 
proteins were then reduced with 50 μl of reduction solution (10 mM of dithiotreitol 
(DTT) in 50 mM NH4HCO3) and the cysteine amino acids were alkylated using 50 μl of 
alkylated solution (55 mM iodoacetamide solution, containing 50 mM of NH4HCO3). 
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Enzymatic digestion was performed by adding 25 µl of a trypsin solution (a 20 ng/ml 
trypsin in 25 mM solution of NH4HCO3) to the gel pieces, and incubated at 37
o
C, for 30 
minutes, and the excess trypsin solution was remove and replaced with 3µl of a 25 mM 
solution of NH4HCO3 to keep the gel wet. The gel pieces were then incubated again at 
37
o
C, overnight. The peptides extraction buffer was composed of 50% of acetonitrile and 
0.1% of trifluoroacetic acid (TFA). The extracted peptides were further purified using Zip 
Tips C18. 
2.2.8 MALDI-TOF/TOF-MS analysis 
The extracted intact cryptocyanin protein was analyzed using a MALDI-
TOF/TOF-MS instrument (Applied Biosystems, 4800 MALDI TOF/TOF Analyzer, 
International-MDS Sciex, Foster City, CA, USA), with a 200-Hz frequency Nd: YAG 
laser. The intact protein sample (2mg/ml) was mixed with an equal volume of sinnapinc 
acid (10 mg/ml, in 50% acetonitrile solution) and spotted on the MALDI plate.
[14,15]
 The 
mass calibration of the MALDI-TOF/TOF-MS instrument was performed using a pure 
Bovine Serum Albumin (BSA) protein solution (2 mg/ml), looking at the following 
molecular ions: [M+H]
 +
 at m/z 66431.2213, [M+2H]
 2+
 at m/z 33216.3776 and [M+3H]
 3+
 
at m/z 22144.1304. The spotting of the analyte and matrix on the MALDI plate was done 
as described below. 
2.2.9 MALDI-QqTOF-MS 
 The digested cryptocyanin protein was analyzed by MALDI-QqTOF-MS and low-
energy CID-MS/MS on an API-QSTAR XL Quadrupole-orthogonal time-of-flight 
QTOF-MS/MS hybrid instrument (Applied Biosystems, International-MDS Sciex,Foster 
City, CA, USA) using a o-MALDI source. Briefly, 1 µl of a 20 mg/ml solution of α-
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CHCA dissolved in ACN, 0.1% TFA was spotted with 1 µl of 2mg/ml of digested sample 
on the MALDI plate and dried at room temperature. The extracted peptides were further 
purified using Zip Tips C18.The calibration of the instrument was performed in the range 
of 600-3200 Da, using standards peptide molecular ions known to be present in the 
BSA.
[16-26]
 
2.2.10 MALDI-QqTOF-CID-MS/MS  
The digested peptides were sequenced by MALDI-QqTOF-low-energy CID-
MS/MS using the same QqTOF-MS/MS hybrid instrument described above. The sample 
preparation by in-gel trypsin digestion was carried out as described previously, and a 
mixture of 50 % ACN and 0.1% TFA was used for the peptides extraction. The extract 
from the in-gel protein spot digestion was trapped on a Millipore C18 Zip Tip (15-20) 
sample aspiration. 1 µl of the 2mg/ml digested and eluted sample was spotted directly on 
the MALDI plate with an equal volume of 1 µl of a 20 mg/ml solution of α-CHCA 
dissolved in ACN, 0.1% TFA, and allowed to dry. The target was inserted into the o-
MALDI source and the spectra were acquired with the Analyst QS software operating 
under control of the o-MALDI server software. The laser was operated at a rate of 20Hz 
and at a calibrated intensity of 40 µJ. An initial survey (peptide mass map) scan of singly 
charged peptide ions was acquired over the course of 1 min with the mass range m/z 600-
3200 with Q1 and Q2 set to run at full transmission mode. MS/MS spectra were then 
acquired with Q1 set to allow the complete isotope spectrum of the selected ions to pass 
into Q2 where CID-MS/MS was performed in presence of nitrogen. The Analyst QS 
software (ABI/MDS Sciex) was used to set the lower mass range of the MS/MS to m/z 50 
and the upper limit to that of the parent ion. The CID-MS/MS of each precursor ion was 
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acquired using the Multi-Channel Analysis (MCA) mode generating an average spectrum 
of different scans monitored at different collision energies.  It is important to state that for 
all the CID-MS/MS sequencing we used the [M+H]
+
 monoisotopic m/z values of the 
released peptides using MS/MS ions search of the ‘Mascot search engine’. 
2.2.11 Peptide mass fingerprint and MS/MS ion searches 
 Identification of the cryptocyanin protein from the PMF and MS/MS ion 
searches was carried out using the Mascot search engine on the National Center for 
Biotechnology Information Non-redundant protein database (NCBInr). The search 
parameters used were: one missed cleavage allowed, carbamidomethyl cysteine (Cys 
CAM) was introduced as a fixed modification, methionine oxidation was set as a variable 
modification, and the peptide mass tolerance was fixed at ± 0.2 Daltons (Da). No other 
constraints were submitted. 
[25, 26]
  
2.3 Result and discussion 
2.3.1 SDS-PAGE purification of the cryptocynin 
 
The SDS-PAGE of the purified hemolymph proteins obtained during molting and non-
molting showed different protein bands above 75 kDa (Figure 2.1). However, we 
observed that the concentration of the 75kDa protein is higher in the molting crab 
hemolymph, when compared to the non-molting crab. The elemental analysis of the 75 
kDa gel band using the atomic absorption spectrometer indicated the total lack of copper. 
Therefore, we can propose that this protein corresponds to cryptocyanin.  
 It is imperative to mention, that we have attempted to improve the SDS-PAGE 
electrophoresis purification of the cryptocyanin protein by increasing the percentage of 
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polyacrylamide gel from 8% to 12%. Unfortunately, with the increase in the gel 
concentration, the separation between the cryptocyanin and hemocyanin bands 
disappeared and united to form an undistinguishable band. 
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Figure 2.1 SDS-PAGE comparison of hemolymph proteins sampled from juvenile crabs 
during their molting and nonmolting processes. 
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In order to confirm that the cryptocyanin band did not coalesce with the 
hemocyanin subunits adjacent heavy band, containing copper, we have experimentally 
differentiated and distinguished the cryptocyanin and hemocyanin bands. It has been 
reported in the literature, that ablation of the crab eyestalk affects the crustacean molt 
inhibiting hormones (MIH) and consequently stops the production of cryptocyanin. It was 
reported that MIH is synthesized and stored in the X organ/sinus gland complex of the 
eyestalk of the crab and it has a major effect on the expression and catabolism of 
cryptocyanin.
[3-11]
 For this reason, we carried out the surgical ablation of the eyestalk of 
juvenile snow crabs, which theoretically stops the cryptocyanin formation during the 
molting process.
[4]
 Therefore, three hemolymph samples were collected, 7 days following 
the ablation, and analyzed by SDS-PAGE electrophoresis. These analyses showed that the 
cryptocyanin gel band has disappeared on the samples collected 14 and 21 days after the 
eyestalk ablation (Figure 2.2) 
[3-6]  
In the following section, we will trek around the similarities and differences 
between the molting and non-molting cryptocyanin proteins analyzed by mass 
spectrometry. We have initially used MALDI-TOF/TOF-MS instrument for the detection 
of the molecular masses of the intact cryptocyanin proteins and MALDI-QqTOF-MS 
hybrid instrument for the peptide mass fingerprinting (PMF) protein identification, and 
finally MALDI-QqTOF-MS/MS for the sequencing of the molting and non-molting 
cryptocyanin proteins. 
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Figure 2.2 SDS-PAGE separation of molting crab hemolymph proteins stained with 
Coomassie Blue stain: (A): no eyestalk ablation was performed; (B): after 7 days ablation 
of eyestalk; (C): after 21 days eyestalk ablation; and (D): after 14 days eyestalk ablation. 
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2.3.2 MALDI-TOF/TOF-MS determination of the molecular mass of the 
cryptocyanin proteins during the non-molting and molting stages  
 
 The 75 kDa SDS-PAGE band of molting cryptocyanin protein was cut and the 
extracted purified protein was subjected to further analysis. The MALDI-TOF/TOF-MS 
of the extracted and purified protein showed the presence of the protonated molecule 
[M+H]
+
 at m/z 67619.56 and the bis-protonated molecule [M+ 2H]
2+
 at m/z 33810.75 
(Figure 2.3a).  
Similarly, the 75kDa gel SDS-PAGE band of the non-molting stage was cut and 
the extracted purified cryptocyanin protein was subjected to further analysis. The 
MALDI-TOF/TOF-MS of the extracted and purified protein showed the presence of the 
protonated molecule [M+H]
+
 at m/z 68132.86 and a bis-protonated molecule [M+2H]
 2+
 at 
m/z 34110.53 (Figure 2.3b). 
It is noteworthy to mention, that we have noted blatant differences between the 
proteins molecular masses observed during the SDS-PAGE and those which were 
measured by MALDI-TOF/TOF-MS.  These differences were attributed to the presence 
of the high number of proline residues (heavy amino acid), which are known to slow 
protein migrations during SDS-PAGE, thus making it appearing heavier than it actually 
is.
[27, 3] 
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Figure 2.3 MALDI-TOF-MS of the intact cryptocyanin protein (a) during the molting 
period and (b) during the non-molting period. 
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2.3.3 Peptide mass fingerprinting of the molting cryptocyanin 
 
 The 75 kDa protein band of the SDS PAGE separation of the extracted and 
purified molting hemolymph proteins was subjected to trypsin digestion for the purpose 
of PMF identification by MALDI-QqTOF-MS (Figure 2.4). Therefore, as a result of 
using the peptide mass fingerprint database, the sequences of the digested peptides were 
matched with other types of cryptocyanin in the Mascot library. These were derived from 
three different species with four accessions, namely: (gi|121484232) for cryptocyanin 1 
[Portunus pelagicus], (gi|81230850) for cryptocyanin 2 [Metacarcinus magister], 
(gi|24658770) for CG3499 [Drosophila melanogaster], and (gi|28557619) for RE25996p 
[Drosophila melanogaster].  
The statistically significant scores reported for Metacarcinus magister were as 
follows: a score of 108, an expectation value 3e
-05
 and 28 matching peptides; whereas for 
the Portunus pelagicus had a score of 74, an expectation value 0.075 and 19 matching 
peptides. Like the Chionoecetes opilio both these species (Portunus pelagicus and 
Metacarcinus magister) are crustacean crabs and provided us with an additional evidence 
for assigning the purifed band as cryptocyanin. We have presented in this work, only the 
matching peptides obtained from the digested cryptocyanin protein obtained from the 
molting stage and these are shown in Table 2.1. 
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Figure 2.4 MALDI-QqTOF-MS of ’in gel’ trypsin digestion of snow crab during the 
molting process. 
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Table 2.1 List of matching peptides obtained from the peptide mass fingerprint (PMF) 
obtained by MALDI-QqTOF-MS analysis of the digested molting cryptocyanin 
Observed ion 
(m/z) 
Mr (exp) 
Calculated 
Mr 
Mass 
Sequence*T Deviation 
(Da) 
602.3824 601.3751 601.3911 -0.0160 K.KSVIR.I* 
2
 
655.3375 654.3302 654.3489 -0.0187 R.VAYFR.E 
2
 
667.2876 666.2803 666.2973 -0.0169 R.YEAER.I 
1,2
 
715.3330 714.3257 714.3449 -0.0192 R.DPAAWR.L 
1,2
 
774.4263 773.4190 773.4436 -0.0245 K.IFEPLR.E 
1,2
 
777.4057 776.3984 776.4181 -0.0197 R.IDNIFR.E 
1,2
 
863.4590 862.4517 862.4735 -0.0217 R.ILAMPYR.D 
2
 
879.4547 878.4474 878.4684 -0.0210 R.ILAMPYR.D + Oxid. (M) 
2
 
916.4829 915.4756 915.4967 -0.0211 K.FGPPFPVR.N 
1
 
931.4325 930.4252 930.4460 -0.0208 K.YHHYGVR.G 
2
 
933.4968 932.4895 932.5192 -0.0297 K.RIDNIFR.E* 
1,2
 
1037.5076 1036.5003 1036.4938 0.0066 K.GNEKGTEFR.L* 
2
 
1082.5260 1081.5188 1081.5781 -0.0593 K.HWAVATNKR.H* 
1,2
 
1120.5699 1119.5626 1119.5825 -0.0199 K.RPFGYPLDR.R 
2
 
1139.4826 1138.4753 1138.5043 -0.0290 K.DTYGYHIDR.K 
1,2
 
1170.6035 1169.5962 1169.5717 0.0245 K.QGFTPQTTYK.F 
2
 
1171.6136 1770.8543 1170.5560 0.0065 K.EGFTPQTTYK.F 
1,2
 
1179.5418 1178.5345 1178.6084 -0.0739 R.LNHKEFTYK.I* 
2
 
1219.5817 1218.5744 1218.5450 0.0293 R.HLMDEFTNGR.L 
1
 
1235.5787 1234.5401 1234.5400 0.0314 R.HLMDEFTNGR.L + Oxid. (M) 
1
 
1267.5732 1266.5659 1266.5993 -0.0334 K.DTYGYHIDRK.G* 
1,2
 
1276.6553 1275.6480 1275.6836 -0.0356 K.RPFGYPLDRR.V* 
2
 
1348.6249 1347.6167 1347.6170 0.0009 R.NDDIHLHDVDR.I 
1
 
1389.7590 1388.7517 1388.7663 -0.0146 R.ISNHLPPLEELK.L 
2
 
1543.7277 1542.7204 1542.7390 -0.0184 K.AVSFNPLGDVSMYK.D + Oxid. (M) 
1
 
1744.8855 1743.8782 1743.9057 -0.0274 R.GVQPDKRPFGYPLDR.R* 
2
 
1771.8616 1770.8543 1770.8487 0.0065 K.GENFFYAYHQLLNR.Y 
1,2
 
1778.9014 1777.8941 1777.9363 -0.0422 K.YDTPPGVLAHLETLPR.D 
1,2
 
1779.0025 1777.9952 1777.9363 0.0589 K.YDTPPGVLAHLETLPR.D 
1,2
 
1899.9073 1898.9000 1898.9427 -0.0427 R.KGENFFYAYHQLLNR.Y* 
1,2
 
2021.0428 2020.0355 2020.0742 -0.0386 K.NKYDTPPGVLAHLETLPR.D* 
1,2
 
2206.0416 2205.0343 2205.1542 -0.1199 K.ALTFNPVGDVSIYRDGGVAVR.Q* 
2
 
2239.0934 2238.0861 2238.1182 -0.0320 K.FGAPFPIRNDDIQLHDVER.V* 
2
 
2678.3880 2677.3807 2677.4493 -0.0686 K.HSPLTQHVVLPAIYEVKPHHFTK.S 
2
 
* The sequence peptide column marked subscripts 
1
 and 
2
 respectively. (*) indicates a 
sequence with one missed cleavage. 
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2.3.4 MALDI-CID-MS/MS sequecing of the digested peptides obtained from the 
molting cryptocyanin protein 
 
It is worthy to mention that for exploring the MS/MS sequencing data of the 
digested peptides, we conducted all the CID-MS/MS analyses on the monoisotopic 
precursor ion [M+H]
+
  of each peptide.
 
The resulting product ion spectra of the digested 
peptides obtained from the molting cryptocyanin were obtained and submitted to Mascot 
database for MS/MS ion search.
[28, 29] 
 Therefore, we have found that the CID-MS/MS 
peptide sequences matched the same cryptocyanin proteins of the two species with three 
accessions identified previously. These were the following: (gi|121484232) accession for 
cryptocyanin 1 [Portunus pelagicus], (gi|81230850) accession for cryptocyanin 2 
[Metacarcinus magister] and (gi|4191390) accession for cryptocyanin [Metacarcinus 
magister] as shown in Table 2.2 
 Each of the identified peptide which was resulted from the CID-MS/MS analysis 
had a separate statistically significant score and all the matched peptides of cryptocyanin 
are indicated in Table 2.2. The CID-fragmentations of the digested peptides obtained 
from the molting cryptocyanin peptides followed, without any ambiguity, the 
fragmentation routes proposed by Roepstorff and Fohlman.
[28] 
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Table 2.2 CID-MS/MS sequences of the peptides obtained by the digested cryptocyanin 
molting protein.  
Observed 
ion Sequence 
Identified Cryptocyanin peptides in the 
Mascot library 
(m/z) gi|121484232 gi|81230850 gi|4191390 
602.3824 K.KSVIR.I (U) N Y N 
655.3375 R.VAYFR.E N Y N 
667.2876 R.YEAER.I Y Y Y 
715.333 R.DPAAWR.L Y Y Y 
774.4263 K.IFEPLR.E Y Y Y 
777.4057 R.IDNIFR.E Y Y Y 
863.459 R.ILAMPYR.D (U) N Y N 
879.4547 R.ILAMPYR.D+ Oxid. M (U) N Y N 
916.4829 K.FGPPFPVR.N (U) Y N Y 
931.4325 K.YHHYGVR.G N Y N 
933.4968 K.RIDNIFR.E* Y Y Y 
1082.526 K.HWAVATNKR.H* (U) Y Y Y 
1120.5699 K.RPFGYPLDR.R* N Y N 
1139.4826 K.DTYGYHIDR.K Y Y Y 
1267.5732 K.DTYGYHIDRK.G Y Y Y 
1360.6744 R.NDDIHLHDVDR.I (U) Y N N 
1744.8855 R.GVQPDKRPFGYPLDR.R** (U) N Y N 
1771.8616 K.GENFFYAYHQLLNR.Y Y Y Y 
1899.9073 R.KGENFFYAYHQLLNR.Y Y Y Y 
2021.0428 K.NKYDTPPGVLAHLETLPR.D* Y Y Y 
2678.388 
K.HSPLTQHVVLPAIYEVKPHHFTK.S** 
(U) 
N Y N 
 
(*) and (**) indicate a sequence with one and two missed cleavages respectively (U) 
indicates that the identified sequence of the peptide was unique. 
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2.3.5. Peptide mass fingerprinting of the non-molting cryptocyanin 
 
 Similarly, the SDS-PAGE 75kDa protein band of the extracted and purified non-
molting hemolymph proteins was subjected to trypsin digestion for the purpose of PMF 
identification by MALDI-QqTOF-MS (Figure 2.5). 
It is very interesting to note that the PMF analysis of the obtained digested 
peptides matched four different proteins. Of these four proteins, two accessions were 
similar to the molting stage, namely: the (gi|121484232) for cryptocyanin 1 [Portunus 
pelagicus] and (gi|81230850) for cryptocyanin 2 [Metacarcinus magister]. In addition, 
two other species-accessions which were not related to the cryptocyanin of two different 
proteins were identified as:  the LP04011p (gi|21429122) protein of the Drosophila 
melanogaster specie and the WD repeat domain 61 (gi|119619579), a CRA protein 
isoform from the Homo sapiens specie. The statistical significant score of Drosophila 
melanogaster was of 68, an expectation value 0.3 and 30 matching peptides, with the WD 
repeat domain had a score of 79, an expectation value 0.025 and 11 matching peptides 
(Table 2.3).  
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Figure 2.5 MALDI-QqTOF-MS of ’in gel’ trypsin digestion of snow crab during the non-
molting process 
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Table 2.3 List of matching peptides obtained from the peptide mass fingerprint (PMF) 
after MALDI-QqTOF-MS analysis of the digests of the gel band at 75 kDa of non-
molting stage 
Observed 
ion (m/z) 
Mr (exp) 
Calculated 
Mr 
Mass 
Sequence deviation 
(Da) 
863.4706 862.4633 862.4548 0.0085 R.QEAFAGLK.Q
1
 
895.4852 894.4779 894.4447 0.0333 R.SLYEIDR.W
1
 
916.4910 915.4837 915.4563 0.0275 K.QVHVYDR.V
1
 
917.4968 916.4895 916.4614 0.0281 K.QQGEQLSK.R
1
 
932.4477 931.4404 931.4399 0.0005 K.KHDEFEK.L*
1
 
959.4364 958.4291 958.5083 -0.0792 K.DADLIREK.L*
1
 
1067.4691 1066.4618 1066.5229 -0.0611 K.LASHSCPAPK.E
2
 
1111.5692 1110.5619 1110.4798 0.0821 K.TSIGLFAKFK.S*
1,2
 
1125.5599 1124.5526 1124.5132 0.0394 K.SLAMSSTDTGR.D
1
 
1126.5632 1125.5559 1125.5415 0.0145 R.DEVSVQGHQK.K
1
 
1127.5658 1126.5585 1126.4747 0.0838 -.MMVQASDTGR.D + 2Oxid.(M)
1
 
1141.4890 1140.4817 1140.5081 -0.0264 K.SLAMSSTDTGR.D + Oxid.(M)
1
 
1170.5757 1169.5684 1169.7132 -0.1448 K.VAKLATGLIER.N*
1
 
1171.5936 1170.5863 1170.6972 -0.1109 K.DLAAVSNLLKK.H*
1
 
1220.5833 1219.5760 1219.6197 -0.0437 K.LQVALDENYR.E
1
 
1185.5498 1184.5425 1184.6700 -0.1274 -.MTNQVRPVLK.G
2
 
1226.6118 1225.6045 1225.7142 -0.1097 R.DLAAVEALIRR.E*
1,2
 
1236.5814 1235.5741 1235.6258 -0.0517 K.RPVLSSSDYGR.D
1
 
1258.5769 1258.5696 1257.5594 0.0102 R.DLEHCNALMR.K
1
 
1271.6861 1270.6788 1270.6881 -0.0093 R.EPSNLQSKIQK.H*
1
 
1274.6666 1273.6593 1273.5543 0.1050 R.DLEHCNALMR.K + Oxid.(M)
1
 
1347.6337 1346.6264 1346.6314 -0.0050 R.DVDDTADRIAEK.S*
1
 
1386.7182 1385.7109 1385.7303 -0.0193 R.QSILNEAYLAHK.F 
1,2
 
1389.7643 1388.7570 1388.7412 0.0158 K.LLHADHVDTLQK.F
1
 
1542.7315 1541.7242 1541.8314 -0.1072 K.RQSILNEAYLAHK.F*
1
 
1745.8901 1744.8828 1744.8744 0.0084 R.LEADVAHHGELADQLK.Q
1
 
1761.8367 1760.8294 1760.9057 -0.0763 R.QEAFAGLKQQGEQLSK.R* 
1
 
1762.8220 1761.8147 1761.9274 -0.1127 R.GGLVHPSLYHNLVSNR.R
2
 
1770.8965 1769.8892 1769.9312 -0.0419 K.QKIDQHETAAEFLIK.K*
1
 
1918.9391 1917.9318 1918.0285 -0.0967 R.GGLVHPSLYHNLVSNRR.S*
2
 
2334.9224 2333.9151 2334.0330 -0.1186 -.MMVQASDTGRDLEHCNALMR.K* 
1
 
2335.1442 2334.1369 2334.0337 0.1032 -.MMVQASDTGRDLEHCNALMR.K* 
1
 
2465.1457 2464.1384 2464.2520 -0.1135 
K.ELGDPGYLVTTVLGGTSEMQILR.G+ 
Oxid.(M)2 
Sequence peptide column with subscripts 1 and 2 respectively. (*) indicates a sequence 
with one missed cleavage. 
 88 
 
2.3.6. MALDI-CID-MS/MS sequencing of the digested peptides obtained from the 
non-molting cryptocyanin protein 
The product ion spectra of the digested peptides were submitted to the Mascot 
database for MS/MS ion search. Once more, it is important to state that for the CID-
MS/MS sequencing we used the [M+H]
+
 monoisotopic m/z values of the released 
peptides for the MS/MS ions search  of the ‘Mascot search engine’.  
The obtained MS/MS data matched the respective hemocyanin subunit proteins of 
three different crustaceans: the hemocyanin subunit 4 (gi|57901145) of the Metacarcinus 
magister, the hemocyanin subunit 3 (gi|57901143) of the Metacarcinus magister and 
hemocyanin alpha-subunit (gi|7105883) of the Homarus americanus (Table 2.4).  
As previously mentioned, we have indicated that the crab cryptocyanin protein 
was created from the duplication of the hemocyanin gene. Therefore, it was no surprise 
that we identified non-molting cryptocyanin peptides that matched a number of the 
peptides of the six hemocyanin subunits. These matching non-molting peptides are 
indicated in Table 2.4. 
It is worth mentioning that for the MS/MS of the protonated molecules extracted 
from the digested molting peptides, described in section 4, none of the sequences of these 
peptides could be matched to the peptides originating from the six hemocyanin subunits. 
This means that these molting peptides were modified during the molting process to adapt 
to their new biological functions.  
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Table 2.4 CID-MS/MS sequences of the peptides obtained the digested cryptocyanin 
non-molting protein.  
Observed ion 
Sequence 
Identified Cryptocyanin peptides in 
the Mascot library 
(m/z) gi|57901145 gi|57901143 gi|7105883 
637.2000 R.FDAER.L* Y Y Y 
752.3000 R.DPAFFR.L* Y Y N 
958.4000 K.YMDNIFR.E* Y Y N 
1110.5000 K.RPHGYPLDR.H*(U) N Y N 
1166.5000 R.LNHEEFSYK.I*(U) N N Y 
1384.7000 K.VYEDIRDPHLK.E*(U) Y N N 
The matching (*) indicate a sequence with one missed cleavages (U) indicates that the 
identified sequence of the peptide was unique 
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2.3.7 Structural similarities and differences between the identified peptides of the 
digested cryptocyanin protein in molting and non-molting snow crab 
 We compared the CID-MS/MS measurements of the digested molting and non-
molting cryptocyanins to show the similarities and differences between the protonated 
peptides. For that reason, once more the product ion scans of identical series of 
monoisotopic m/z value, for both the digested molting and non-molting cryptocyanin 
peptides were recorded. Accordingly, we measured a series of 15 product ion scans from 
the individual extracted protonated molecule of these peptides, which were respectively 
assigned with the Mascot library. The structures of these peptides were determined as 
follows: VAYFRE at m/z 655.3381, VATVSLPR at m/z 842.4919, FGPPFPVRN at m/z 
916.4829, QQGEQLSKR at m/z 917.4968, YHHYGVRG at m/z 931.4401, KHDEFEKL 
at m/z 932.4477, RIDNIFRE m/z 933.4968, VLHPVTNRK m/z 934.5133, 
HWAVATNKRH at m/z 1082.5324, RPFGYPLDRR at m/z 1120.5604, SFVEANPELR 
m/z 1161.5891, RAVLPSMSSAR at m/z 1190.5574 and DVDDTADRIAEKS m/z 
1347.6337 AQLLAMMDTMMGGR at m/z 1541.7257, and 
NKYDTPPGVLAHLETLPR.D at m/z 2021.0428. 
 Actually, seven of these similar [M+H]
+
 ions of the peptide sequences were 
assigned with matched sequences of cryptocyanin of different species (Portunus pelagicus 
and Metacarcinus magister); VAYFRE at m/z 655.3381, FGPPFPVRN at m/z 916.4829, 
YHHYGVR at m/z 931.4401, RIDNIFRE at m/z 933.4968, HWAVATNKRH at m/z 
1082.5324, RPFGYPLDRR at m/z 1120.5604, and NKYDTPPGVLAHLETLPR.D at m/z 
2021.0428 (full sequence is shown in Fig. 2.6). On the other hand, the remaining eight 
similar [M+H]+ ions of the peptide sequences were assigned with other matched 
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sequences of different proteins of different species (Drosophila melanogaster and Homo 
sapiens); VATVSLPR at m/z 842.4919, QQGEQLSKR at m/z 917.4968, KHDEFEKL at 
m/z 932.4477, VLHPVTNRK at m/z 934.5133, SFVEANPELR at m/z 1161.5891 
RAVLPSMSSAR at m/z 1190.5574, DVDDTADRIAEKS at m/z 1347.6337, and 
AQLLAMMDTMMGGR at m/z 1541.7257.  
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1 MKVLVVFALV ALSAAAAQAN EPDGIPTYQK QHDVNNALYK IFEPLREDNL 
51 RDKALTFNPV GDVSIYRDGG VAVRQLMYEL THDRLLEKKH WAVATNKRHL 
101 EEAIMLFEVF MQCKDWNCAA SNAAYFRERV NEEEFIYAAY HAVKHSPLTQ 
151 HVVLPAIYEV KPHHFTKSQV INEAYEAKEM KLRNIYFQNN FTGTPNDIEH 
201 RVAYFREDIG VGTHHLMINL ENPCWWKDTY GYHIDRKGEN FFYAYHQLLN 
251 RYEAERISNH LPPLEELKLD EPLKQGFTPQ TTYK.FGAPFP IRNDDIQLHD 
301 VERVGRIHEI VHLEDRIHDA IAHGYVEDEQ GNKINIENDQ GIDIIGDIIQ 
351 SSLYSPNRKY YGNLTTLAYN MLDHQTDPKN KYDTPPGVLA HLETLPRDPA 
401 AWRLHKRIDN IFREHIDSLP PYTKEQLEFT GISVENVQIQ GNLETYFEEY 
451 KYDLINGFND NTTQTEFYGI YATMPRLNHK EFTYKINVQN NNGTPKKSVI 
501 RILAMPYRDG NGAIISFDEG RWLAIEMDLF VKTLTEGKNE IIRKSSEASI 
551 TVPDVPTYKT LVEMTEDHQS LERYESATGI PNRLLLPKGN EKGTEFRLVV 
601 AATNAEEDIN DESIITMNKY HHYGVRGVQP DKRPFGYPLD RRVFDEHIVN 
651 EVSSIKETMV KVYNHDVLIR LPHY 
  
 
 
1 DEPDGVSKYQ KQHDVYYAFY KIFEPLRESN LVEKAATFNP VGDVSMYKDG 
51 GVAVQNLMYE LTHQRLLEKK HWAVATNKRH LEEAIMLFEV FMQCKDWNCV 
101 ASNAAYFRER VNEEEFIYAA YHAIKHSPLT QHVVLPAIYE VKPRHFTKTQ 
151 IAEEAYEAKE MKLRNVFFQN NFTGTPNDIE HRVAYFREDI GVGTHHLMIH 
201 LENPFWWKDT YGYHIDRKGE NFFYAYHQLL NRYEAERISN HLPPLEELKL 
251 DKPLKQGFAP QTTYNFGGPF ATRNDNVHLQ DVDNVGRIHE IVHMEDRIHD 
301 AIAHGYVEDE QGNKINIENE QGIDILGDII QSSLYSPNRK YYGNLTTLAY 
351 TMLDHQTDPK NKYDTPPGVL AHLETLPRDP AAWRLHKRID NIFREHIDSL 
401 PPYTKEQLEF TGITVSDVQI QGSLETYFEE YKYDLINGLN DNTTETEFYG 
451 IYATMPRLNH KEFSYKIHVQ NNNGASKKAV IRLLAMPYRD GNGAIIPFDE 
501 GRWLAIEMDL FVKTLTSGDN EIDRKSSEAS ITVPDVPTYK TLVEKTENRE 
551 NLEMYESSTG IPNRLLLPKG CEEGTEFRLP VAVTDAENDV NDESIITMQK 
601 YHHYGVRGVQ PDNRPFGYPL DRRVPDEHIV DEVSNIKATM VKVYNHNVFI 
651 PLS 
    
      
 
1 MKLLVILALV ALTGASAWPN FMSDEPDGVP AHQKQHDVNY AFYKIFEPLR 
51 DNNLAEKAVS FNPLGDVSMY KDGGVAVRHL MDEFTNGRLL EKKHWAVATN 
101 KRHLEEAIML FEVFMQCRDW NCVASNGAYF RERVNEEEFI YAAYHAIKHS 
151 PLTQHVVLPA MYEVKPHHFT KTQVIEEAYE AKEMKLRNII FQNNFTGTPN 
201 DIEQRVAYYR EDVGVGTHHL MIHLENPFWW KDTYGYHIDR KGENFFYAYH 
251 QLLNRYEAER ISNYLPPLQE LKLDEPLKEG FTPQTTYK.FG PPFPVRNDDI 
301 HLHDVDRIGR IHEVVHMEDR IHDAIAHGYV EDEQGNKINI DNDHGIDILG 
351 DIIQSSMYSP NRKYYGNLTT LAYTLLDHQT DPKNKYDTPP GVLAHLETLP 
401 RDPAAWRLHK RIDNIFREHI DTLPPYTKE 
  
 
 
(a) Full sequence of cryptocyanin 2 [Metacarcinus magister] 
(b) Full sequence of cryptocyanin [Metacarcinus magister] 
(c) Full sequence of cryptocyanin 1 [Portunus pelagicus] 
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Figure 2.6 The matched peptides locations of cryptocyanin in different species. The 
matched peptides during molting process were coloured in red. The green matched 
peptides were sharing in both molting and non-molting stages. The underlined sequence 
indicates to isobaric peptides 
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We have chosen to illustrate in this discussion the MS/MS data of the peptide 
HAWAVATNKR at m/z 1082.5324 from the aforementioned series, as a show case 
common peptide example for the digested molting and non-molting cryptocyanin protein. 
Hence the CID-MS/MS spectrum of the protonated molecule at m/z 1082.5324 is shown 
in Figure 2.7a and the identified product ions are reported in Table A.1 (supplementary 
information). 
In addition, we also recognized from this series, the presence of numerous isobaric 
peptides of the cryptocyanin protein from the molting and non-molting stages (Table 2.1 
and 2.3). As an example, we are only showing one protonated peptide molecule at m/z 
916.4829, which could be assigned to two different peptide structures, either 
FGPPFPVRN and/or QVHVYDRV. It is interesting to note that these two isobaric 
peptides, matched respectively two different proteins of different species, namely: the 
cryptocyanin protein of Portunus pelagicus and the ‘LP04011p protein of Drosophila 
melanogaster.  Hence, in this manuscript, we have assigned the peptide ‘FGPPFPVRN’ at 
m/z 916.4829 to the cryptocyanin of Portunus pelagicus, as it is the closest specie to 
Chionoecetes Opilio. Accordingly, Figure 2.7b illustrates the MS/MS of the FGPPFPVR 
peptide at m/z 916.4829 and the identified product ions are listed in Table A.2 
(supplementary information).  
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Figure 2.7 MALDI-CID-MS/MS of the [M+H]+ ions obtained from the tryptic peptides 
of themolting and non-molting cryptocyanins: (a) HAWAVATNKR at m/z 1082.5324 
and (b) FGPPFPVR at m/z 916.5099. 
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In addition, we concluded that without any doubts the MS/MS data correlate the 
peptide sequences identified during the PMF analysis. In the several paragraphs discussed 
above, we have indicated the structural similarities between the digested molting and non-
molting cryptocyanin peptides. 
 Unquestionably, it is fundamental to distinguish the structural differences 
between the protonated peptides of the molting and non-molting cryptocyanin peptides. In 
the following section we will discuss their structural differences.   
As described earlier, we have anticipated that such differences and/or 
modifications between the peptides of the molting and non-molting digested 
cryptocyanins must be inherent of a biosynthetic alteration, which occurs in order to 
prepare the cryptocyanin to adapt to its new biological function. This biosynthetic 
alteration of the cryptocyanin is attributed to its new role as a key player in forming the 
new exoskeleton during the molting process. For these reasons, it is understandable that 
some of the characterized molting cryptocyanin peptides will result from modification of 
the original peptides present in the non-molting cryptocyanin protein. On the other hand, 
it is important to remember that during the non-molting process, the cryptocyanin protein 
maintains its normal physiological functions such as cardiovascular function and ion 
regulation.
[3]
  
Concurrently, for the characterization of the obtained unique molting peptides we 
have chosen two discriminating modified peptides for CID-MS/MS sequencing which 
were considered as unique peptides for the molting cryptocyanin. Consequently, both the 
product ion scans of the [M+H]
+ 
precursor protonated peptides DGNGAIIPFDEGR at m/z 
1360.6744 and GVQPDKRPFGYPLDRR at m/z 1744.8554 are shown in Figures 2.8a 
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and 2.8b. The identified respective product ions are presented in Tables A.3 and A.4 
(supplementary information). These series of product ions are indeed diagnostic for the 
molting stage cryptocyanin protein.  
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Figure 3.8 MALDI-CID-MS/MS of the [M+H]
+
 ions of both the exclusive tryptic 
peptides of molting cryptocyanin: (a) DGNGAIIPFDEGR at m/z 1360.6744 and (b) 
GVQPDKRPFGYPLDRR at m/z 1744.8554. 
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In a similar manner, we conducted six additional CID-MSMS analyses of selected 
precursor protonated peptide ions, diagnostic of the non-molting stage cryptocyanin 
protein. As already discussed, the structures of these six chosen peptides are matched to 
the structure of the six hemocyanin subunits. Henceforth, the product ion scan of the 
following peptides FDAER at m/z 637.2853, DPAFFR at m/z 752.3832, YMDNIFR at 
m/z 958.4520, RPHGYPLDR at m/z 1110. 5552, LNHEEFSYK at m/z 1166. 5525 and 
VYEDIRDPHLK at m/z 1384.7427 are shown in Figures 2.9a, 2.9b, 2.9c, 2.9d, 2.9e and 
2.9f and the identified product ions are displayed in Tables A.5, A.6, A.7, A.8, A.9 and 
A.10  (supplementary information), respectively.  
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Figure 2.9 MALDI-CID-MS/MS of the [M +H]
+
 ions of the tryptic changed and/or 
modified peptides obtained from nonmolting cryptocyanin (a) FDAER at m/z 637.2000, 
(b) DPAFFR at m/z 752.3000, (c) YMDNIFR at m/z 958.4000, (d) RPHGYPLDR at m/z 
1110.5000, (e) LNHEEFSYK at m/z 1166.5000, and (f) VYEDIRDPHLK at m/z 
1384.7000 
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It is important to note that from the six selected non-molting precursor protonated 
peptide ions described previously, we were capable of choosing three characteristic and 
unique peptide ions. These were assigned as follows: RPHGYPLDR at m/z 1110.5000, 
LNHEEFSYK at m/z 1166.5000 and VYEDIRDPHLK at m/z 1384.7000. In that instance, 
it is important to mention that the selection criterion for the characterized unique peptide 
ions was based on very simple criteria. Hence, initially, the chosen peptides have to be 
free of post-translational modifications. In addition, the choice of these unique peptide 
ions must respect the different following theoretical, empirical and technical caveats. 
From the theoretical point of view, the peptide sequences should be free of methionine 
and cysteine to avoid amino acid modifications, which may occur during the digestion of 
the protein by either the oxidation of the methionine (Met) and/or carbomidomethylation 
of the Cys residue. As well, the empirical and technical properties are based on the signal 
intensity of the peptide ions obtained during the various mass spectrometric analyses.
[31]
 
In view of that, the strongest peptide ion signals are preferred over the others because of 
their high sensitivity and their lower limit of detection. Furthermore, the selection of the 
precursor peptide ions is also based on their high susceptibility to fragment under CID 
conditions, and to produce abundant high molecular mass product ions.
[31]  
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2.4 Conclusion 
In this report, we have demonstrated for the first time, using MALDI TOF/TOF-
MS, that the actual molecular mass of the cryptocyanin protein in the snow crab 
(Chionoecetes opilio) during molting and non-molting phases. The peptide mass 
fingerprinting (PMF) was conducted using an MALDI-QqTOF-MS hybrid instrument.  
The MALDI-CID-MS/MS analyses allowed the sequencing of the cryptocyanin 
protein after tryptic digestion, during the molting and non-molting stages. These CID-
MS/MS analyses showed some similarities and staggering differences between the 
identified cryptocyanin peptides of the two different stages.  
In quest for developing a “signature peptides” method for monitoring the levels of 
the cryptocyanin protein during the molting and non-molting stages in the hemolymph, 
we compared the identified peptides of this protein in the two different stages.  
We have shown that six peptides of the non-molting cryptocyanin matched the 
known hemocyanin peptides. These were selected as diagnostic peptides to elucidate the 
ability of snow crab to change its genetic code for adaptability to new biological functions 
during molting.  
Appendix A. Supplementary data 
Supplementary are data associated with this chapter (P.165) 
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3.1 Introduction 
The cytotoxic T cells (CD8+ T cells) play an important role in fighting cancer 
cells through recognizing the TACAs in a conventional class I MHC-restricted fashion.
[1-
9] 
Generally; cancer cells are often characterized by changes in their shape and size.  
These cancer cells attack and invade normal healthy cells and their surrounding 
environment.
[1-9] 
One of the most noticeable changes during progression of cancer is the 
aberrant glycosylation.
[8-10]
 Accordingly, in some forms, the resulting increase in the 
numbers of glycosylation sites are reflected by the presence of the TACAs such as; Tn 
(GalNAcα1→Ser/Thr), sialyl-Tn (Neu5Acα2→6GalNAc) and Thomsen-Friedenreich 
(TF: Galβ1→3GalNAcα1→Ser/Thr) antigens.[11-14]   
The TF tumor associated antigen (Galβ1→3GalNAcα1→Ser/Thr) is present on 
the core 1 structure of O-linked mucin type glycan (MUC-1). This TF tumor associated 
antigen is formed by a disaccharide composed of one D-Galactose and one D-GalNAc 
residue attached by a β-D-(1→3) glycosidic linkage. Moreover, this disaccharide is linked 
by an α-D-(1→O) bond to the L-serine or L-threonine residues.[14,15]  
It was observed that this antigen is heavily expressed in several carcinomas, such 
as those of breast, colon, bladder, and prostate.
[13,15-18] 
Nevertheless, 90% of human 
cancer cells possess the tumor associated Galβ1→3GalNAc antigen on their epithelial 
tissues, in contrast to normal cells which are covered by sialic acids and sulphates 
groups.
[12] 
 
Different studies have been carried out on the use of the TF antigen as a target for 
the design of different cancer vaccines.
[18-23]
 For example, Heimburg et al. found that the 
anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11 inhibited spontaneous 
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breast cancer metastasis.
[23]
 More recently, Hoffmann-Röder et al. prepared several 
synthetic antitumor vaccines composed of tetanus toxoid conjugates of Mucin 1 (MUC1) 
glycopeptides with the Thomsen-Friedenreich antigen (TF-MUC1-BSA conjugate) and a 
fluorine-substituted analogue (difluoro-TF-MUC1-BSA conjugate).
[24] 
These authors also 
conjugated the tandem-repeat sequences of the epithelial mucin MUC1 containing the TF 
and/or its difluoro-TF saccharide side chains to the tetanus toxoid protein carrier.
[24]
 
Different protein carriers such as keyhole limpet hemocyanine (KLH), diphtheria 
toxoid (DT), cross-reactive material 197 (CRM197) and tetanus toxoid (TT) have been 
used for the synthesis of various anticancer carbohydrate-based vaccines.
[25-27]
 In these 
syntheses the carbohydrate antigens used were often allyl or pentenyl glycosides 
convertible into an aldehyde for subsequent attachment to the immunogenic protein 
carriers via reductive amination.
[20-27]
 In addition, other frequently employed chemical 
ligation involved the 1,4-conjugate addition of multiply thiolated proteins onto maleimido 
derivatives
.[28-30] 
To the best of our knowledge, the systematic use of the L-lysine -amino groups 
of the protein carrier, has scarcely been investigated as nucleophilic partners for the 
chemical ligation by a 1,4-conjugate addition.
[31-33]
 Furthermore, the detailed structural 
identity of the glycoforms which are resulted from the 1,4-conjugate addition (Michael 
reaction) has never been used for the conjugation of the anticancer TF to BSA as a protein 
carrier.
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In this manuscript, we have characterized two synthetic TF:BSA protein conjugate 
based vaccines and have revealed the respective C-N and C-S glycation sites of the 
synthetic TF to the various amino acid residues of bovine serum albumin protein (BSA).  
3.2 Material and methods 
3.2.1 Preparation of the TF-BSA vaccine conjugate 
The TF was prepared according to a published procedure.
[33]
 Briefly, the 
photocatalyzed reaction of the allyl glycoside of Thomsen–Friedenreich (TF) 
disaccharide [allyl 3-O-(β-D-galactopyranosyl)-2-acetamido-2-deoxy-α-D-
glucopyranoside] 1 with cysteamine gave the TF glycoside derivative 2 with a terminal 
primary amino group in 83% yield. Subsequently, compound 2 was treated with acryloyl 
chloride in methanol to yield the α,β-unsaturated amide derivative 3 via the nucleophilc 
displacement of the chloride with the amino function. This reaction was carried out in the 
presence a strong base anion resin to remove the formed HCl. Finally, the acrylamide-
ending TF 3 was anchored to the BSA carrier protein by treating the α,β-unsaturated 
amide with BSA at room temperature and at 40 °C, respectively in a 0.2 M carbonate 
buffer for 3 days to afford the two desired TF-BSA anti-tumor vaccine conjugates having 
a low and a high TF-content. A colorimetric phenol-sulfuric acid test was performed onto 
the BSA-TF conjugates using compound 1 a standard.
[34] 
The analysis showed the 
conjugates to contain 2±1 and 8±2 TFs, respectively.  
3.2.2 Trypsin digestion of the glycoconjugate  
The digestion of the hapten-BSA glycoconjugate was carried out with trypsin 
(Sigma Aldrich, Saint Louis, MO, USA). Thus, 100 µg of the glycoconjugate was 
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dissolved in a mixture of 0.1% RapiGest SF Surfactant (1 µg, Waters, Milford, MA, 
USA) in 50 mM of NH4HCO3 (100 µl) at a pH of 8.0 and reduced by treatment with 2 µl 
of 10mM dithiothreitol (Sigma Aldrich, Saint Louis, MO, USA) for 30 min at room 
temperature, followed by alkylation with 2 µl of 50 mM iodoacetamide (Sigma Aldrich, 
Saint Louis, MO, USA) for 1 h at room temperature. A portion (50 µg) of the 
glycoconjugate was digested with trypsin using a 20 ng/ml solution of trypsin dissolved 
in NH4HCO3 (50 mM, 1 ml) at a trypsin-glycoprotein ratio of 1:25 (w/w) and incubated at 
37°C overnight with shaking. The sample was then dried under vacuum, and the residue 
was dissolved in 20 µl of 1% acetic acid (Sigma Aldrich, Saint Louis, MO, USA). An 
aliquot of each sample (10 µl) was then cleaned up using ZipTip C18 (Millipore, 
Bedford, MA, USA) before mass spectral analysis. 
3.2.3 MALDI-TOF-MS analysis 
MALDI-TOF-MS analysis was carried out on a 4800 Proteomics analyzer with 
TOF/TOF optics (Applied Biosystems Foster City, CA) (FWHM 20,000) and a 200-Hz 
frequency-tripled Nd:YAG laser. α-Cyano-4-hydroxycinnamic acid (α-CHCA) was used 
as matrix for the analysis of BSA and hapten-BSA conjugates with an average of 5000 to 
8000 laser shots per spectra. Briefly, 1 µL of a 20 mg/mL solution of α-CHCA (dissolved 
in ACN, 0.1% trifluoroacetic acid) was spotted on the MALDI plate and dried at room 
temperature (the use of ACN allows a good homogeneity of the matrix in the spot). Then, 
an aliquot of 1 µL of sample was spotted on the top of the dried matrix and allowed to dry 
before the MALDI-MS experiments. The analysis was achieved in the linear mode 
(positive ion mode) and the MALDI-TOF-MS was calibrated using BSA. 
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3.2.4 LC-ESI-QqTOF-CID-MS/MS analysis 
 The trypsin released glycopeptides and peptides were separated on a DIONEX 
UltiMate3000 Nano LC System (Germering, Germany). 250 fmol of digested 
glycoprotein was dissolved in 0.1% TFA and loaded onto a precolumn (300 µm i.d. x 5 
mm, C18 PepMap100, 5 μm (LC Packing, Sunnyvale, CA)) in order to desalt and 
concentrate the sample. After their elution from the precolumn, the peptides and 
glycopeptide mixtures were separated on a nanoflow analytical column (75 µm i.d. ×15 
cm, C18 PepMap 100, 3 µm, 100, (LC Packing, Sunnyvale, CA)) at a flow rate of 180 
nL/min. The elution of the peptides and glycopeptides was achieved using the following 
mobile phases: 0.1% formic acid (FA)/0.01% TFA/2% ACN (A) and 0.08% FA/0.008% 
TFA/98% ACN (B). The elution started with 0% B for 10 min, followed by a gradient of 
0-60% B in 55 min and 60-90% B in 3 min and was kept at 90% B for 3 min. The tandem 
mass spectrometry analysis of the eluted peptides and glycopeptides was accomplished 
using an Applied Biosystems API-QSTAR XL quadrupole orthogonal time-of-flight 
(QqTOF)-MS/MS hybrid tandem mass spectrometer (Applied Biosystems International-
MDS SCIEX, Foster City, CA, USA) (FWHM 15,000) equipped with a nanoelectrospray 
source (Protana XYZ manipulator) which produces the electrospray through a PicoTip 
needle (10 µm i.d., New Objectives, Wobum, MA, USA) carrying a voltage of 2400 V. 
The TOF analyzer was calibrated on the ions at m/z 586.9815 and m/z 879.9723, derived 
from renin (1 pmol/μL solution). The collision energies used during the CID-MS/MS 
analyses were determined automatically using the Information Dependent Acquisition 
(IDA) method integrated in the Analyst software. 
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3.2.5 MS/MS ion searches 
 Identification of glycoprotein from the MS/MS ions search was carried out with 
the Mascot search engine on NCBInr. The search parameters used were: one missed 
cleavage was allowed, Cys CAM was introduced as a fixed modification, and the peptide 
tolerance was fixed at ± 0.2 m/z unit. No other constraints were submitted.
[35, 36] 
3.3 Results and discussion  
3.3.1 Synthesis of the TF-BSA vaccine conjugate by the Michael addition reaction 
BSA is one of the most widely studied proteins used as a carrier protein for the 
synthesis of neoglycoconjugates.
[27,37-41]
  BSA contains 35 cysteine residues linked by S-S 
disulphide bonds among which, however, there is only a single buried free Cys 34 
residue
[42]
 that has been systematically used for other conjugation.
[43,44]
 It is well known, 
that the 35 cysteine residues of BSA form 17 disulphide bonds at these positions (1) 77-
86; (2) 99-115; (3) 114-125; (4) 147-192; (5) 191-200; (6) 223-269; (7) 268-276; (8) 288-
302; (9) 301-312; (10) 339-384; (11) 383-392; (12) 415-461; (13) 460-471; (14) 484-500; 
(15) 499-510; (16) 537-582; (17) 581-590
.[42, 45-51]
 As a result, the free remaining reactive 
single sulfhydryl (Cys 34) group can serve as potential acceptor for the Michael addition 
reaction with a reactive acceptor. 
In this report, the synthesis of the TF acceptor 3 was carried out by an already 
published strategy using the Michael addition reaction (Scheme 1).
[31-33]
 The Michael 
addition reaction belongs to the larger class of conjugate additions and its mechanism 
involves the attack by biological nucleophile (cysteine or lysine)  at the β-carbon atom of 
the ,-unsaturated Michael acceptor (Scheme 3.1 and Figure 3.1).[49-54]  In order to 
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investigate the possible alternative conjugate addition originating from the lysine -amine 
residues (or other amino acids), we tested various buffers, pH, and stoichiometric 
conditions. To our surprise, at pH 10 in a carbonate buffer at 40°C for three days, we 
found the highly immunogenic conjugated vaccine
 [43,44]
 to contain several copies of the 
TFs.
[31,32] 
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Scheme 3.1 Structure of the TF antigen and its chemical transformation into a suitable 
Michael acceptor 3. 
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The mechanism of the based-catalyzed thio-Michael addition reaction between the 
TF and BSA is governed by the electrophilic addition of the acrylamide aglycone part of 
the disaccharide Galβ1→3GalNAcα, which easily reacts with the free sulphydryl group 
of Cys 34 is illustrated in Figure 3.1.  
In the presented work, we have attempted two different syntheses based on 
different stoichiometry of the glycosyl donor (TF) and acceptor carrier protein (BSA) of 
2:1 and 8:1, respectively. As expected, these conditions resulted in the formation of two 
different TF neoglycoconjugate vaccines.   
The best advantage of the synthetic tactic used for producing the TF:BSA 
conjugate over other existing approaches for protein glycosylation, is that it can be 
applied to cysteine containing proteins (free of disulphide bonds with neibhouring 
residues) in their native form without any additional chemical modification or activation. 
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Figure 3.1 Synthesis of Thomsen–Friedenreich antigen–BSA glycoconjugate vaccines 
using a Michael addition. 
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3.3.2 MALDI-TOF-MS analysis of the TF-BSA glycoconjugates  
For the determination of the average number of carbohydrate-spacer moieties 
linked to BSA (TF: BSA), the two glycoconjugates were analyzed by matrix assisted laser 
desorption/ionization- mass spectrometry (Figure 3.2a and 3.2b and Table 3.1).
[38-41] 
The MALDI-TOF-MS were characterized by the formation of a protonated molecular 
ions [M+H]
+
 at m/z 67599 and 70904 and their TF-BSA ratios were calculated to be 
individually 2:1 and 8:1. 
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Figure 3.2 a) MALDI-TOF-MS analysis of TF:BSA glycoconjugates with ratio= 2:1. b) 
MALDI-TOF-MS analysis of TF:BSA glycoconjugates with ratio = 8:1. 
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The molecular mass calculation of the glycoconjugate formed with a hapten:BSA 
ratio of 2:1, was based on the assumption that one molecule of the TF will covalently 
links by a Michael addition reaction on the free sulfhydryl (Cys 34) group, forming a C-S 
bond. The remaining stoichiometric amount (one molecule) of the TF, can react with 
specific free available ε-amino group of lysine residue of BSA, forming a C-N bond. For 
the glycoconjugate designed with the hapten:BSA ratio of 2:8 we expected similar 
glycation of Cys 34, whereas the seven additional molecules of the TF (hapten)  directly 
targeted the ε-amino  groups of the various lysine residues of BSA, forming a C-N bond, 
which occured by loss of ethanol molecules. 
It is important to recognize that the TF is composed of the disccharide 
Galβ1→3GalNAcα1→O-linked to the spacer [-(CH2)3S(CH2)2NH-CO-CH=CH2] 
(containing the acrylyamide portion) and it has a molecular mass of 555.22 Da (Table 
3.1).  
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Table 3.1. MALDI-TOF-MS of BSA and TF: BSA glycoconjugate vaccines and the 
calculated carbohydrate:BSA ratios 
 
 
[M+2H]
2+
 [M+H]
+
 
TF: BSA  
Ratio 
Standard BSA 33216 66431 - 
TF:BSA 2:1 33800 67599 2.1:1 
TF:BSA 
8:1 
35453 70904 8.1:1 
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3.3.3 LC-ESI-MS and CID-MS/MS analyses of tryptic digest of the glycoconjugate 
with a TF: BSA ratio of 2:1 and 8:1 
Nano-LC-ESI-QqTOF-MS/MS analysis was carried out on both tryptic digests of 
glycoconjugates with TF: protein ratio 2: 1 and 8:1, and this was followed by de novo 
peptide sequencing using low-energy collision dissociation tandem mass spectrometry 
CID-MS/MS to identify the possible S- and N- glycated sites.
[55,56] 
The obtained low-
energy CID-MS/MS were submitted to the Mascot library to identify the glycopeptides 
and peptides released from BSA.   
The Mascot reports of MS/MS data of the tryptic digests of both glycoconjugates 
identified two serum albumin isoforms from Bos taurus species. The serum albumin 
precursor (gi|1351907) was identified with sequence coverages: 46% and 21% for both 
glycoconjugates formed with TF: BSA ratio of 2:1 and 8:1 respectively. In addition, 
serum albumin protein isoform (gi|229552) was also identified for the tryptic digest for 
both glycoconjugates with sequence coverages of 42% for the TF: BSA ratio of 2:1 and 
19% for the glycocnjugated having TF: BSA ratio of 8:1.  
Please note that, the identified glycopeptides m/z values were calculated by adding 
the molecular mass of the carbohydrate TF (Molecular mass, 555.22 Da), to the m/z value 
of the “correct” identified peptides. The “correct” peptide was identified by comparing 
the enzymatically released peptides of both the glycoconjugate vaccine and BSA. This 
comparison  allows the selection of the missing peptide ions from blueprint of the BSA 
digestion. Once these peptides are identified, it is possible to add their respective masses 
to the mass of the carbohydrate TF. This method permits to determine the exact structures 
and masses of the glycated peptides, which sequences are then verified by MS/MS. 
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Following de novo sequencing of the digested glycoconjugate formed with a TF: 
BSA, ratio of 2:1, we were able to identify of 3 glycated peptides (Table 3.2) ;  
FK*DLGEEHFK 4 (C-N glycation site is Lys 12) at 902.11 (+2), 
GLVLIAFSQYLQQC*PFDEHVK 5 (C-S glycation site is Cys 34) at 1015.48 (+3) and 
HKPK*ATEEQLK 6 (C-N glycation site is Lys 535) at 620.54 (+3) (Table 3.2).  
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Table 3.2 CID-MS/MS analysis of the glycated peptides ions obtained by the trypsin 
digestion of the TF:BSA vaccine with ratio 2:1 
 
Sequence of the glycated peptides (* = glycation site) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glycated peptide sequence Missed 
Cleavage 
TF:BSA ratio 2:1 
Molecular 
weight 
Calculated 
m/z 
(charge) 
Observed 
m/z 
(charge) 
Error 
FK*DLGEEHFK (Lys 12) 4 1 1802.18 902.09(+2) 902.11(+2) -0.02 
GLVLIAFSQYLQQC*PFDEHVK  5 
(Cys 34) 
0 3043.61 1015.53(+3) 1015.48(+3) 
 
0.05 
HKPK*ATEEQLK  (Lys 535) 6 2 1858.61 620.53(+3) 620.54(+3) 
 
-0.01 
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Subsequently, de novo sequencing of the digested glycoconjugate formed with a 
TF: BSA, ratio of 8:1, allowed us to identify 14 glycated peptides. The structures of this 
series of glycopeptides are specified in Table 3.3. This series of glycopeptides contained 
the three above-mentioned identifed peptides 4 (C-N glycation site is Lys 12), 5 (C-S 
glycation site is Cys 34) and 6 (C-N glycation site is Lys 535); in which all ions had the 
same charges as previoulsy described. Furthermore, it also contained the following 
peptides: 7 (C-N glycation site is Lys 116) at m/z 1065.58(+2), 8 (C-N glycation site is 
Lys 522) at m/z 848.71(+2),  9 (C-N glycation site is Lys 412) at m/z 731.46(+3), 10 (C-N 
glycation site is Lys 127) at m/z 858.28(+3), 11 (C-N glycation site is Lys 106) at m/z 
818.79(+3), 12 (C-N glycation site is Lys 312) at m/z 1004.26(+3), 13 (C-N glycation site 
is Lys 429) at m/z 685.25, 14 (C-N glycation site is Lys 186) at m/z 765.85(+2), 15 (C-N 
glycation site is Lys 210)  at m/z 777.37(+2), 16 (C-N glycation site is Lys 4) at m/z 
873.42(+2), 17 (C-N glycation site is Lys 179) at m/z 942.63(+2).  
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Table 3.3 CID-MS/MS analysis of the glycated peptides ions obtained by the trypsin 
digestion of the TF:BSA vaccine with ratio 8:1 
 
Glycated peptide sequence Missed 
Cleavage 
TF: BSA ratio 8:1 
Molecular 
weight 
Calculated 
m/z 
(charge) 
Observed  
m/z 
(charge) 
Error 
 
FK*DLGEEHFK  (Lys 12) 4 1 1802.18 902.09 (+2) 902.12(+2) -0.03 
GLVLIAFSQYLQQC*PFDEHVK  
(Cys 34) 5 
0 3043.61 1015.53 
(+3) 
1015.46(+3) 
 
0.07 
HKPK*ATEEQLK  (Lys 535) 6 2 1858.61 620.53 (+3) 620.53 (+3) 
 
0.00 
LK*PDPNTLCDEFK (Lys 116) 7 1 2129.33 1065.66(+2) 1065.58 
(+2) 
0.08 
K*QTALVELLK (Lys 522) 8 1 1695.27 848.63 (+2) 848.71 (+2) -0.08 
K*VPQVSTPTLVEVSR (Lys 412) 
9 
1 2191.50 731.50 (+3) 731.46 (+3) 
 
0.04 
LKPDPNTLCDEFK*ADEK (Lys 
127) 10 
2 2571.62 858.20 (+3) 858.28 (+3) 
 
-0.08 
NECFLSHK*DDSPDLPK  (Lys 
106) 11 
1 2453.43 818.81 (+3) 818.79 (+3) 
 
0.02 
DAIPENLPPLTADFAEDK*DVCK  
(Lys 312) 12 
1 3009.74 1004.24 
(+3) 
1004.26 
(+3) 
 
-0.02 
SLGK*VGTR (Lys 429) 13 1 1368.52 685.26 (+2) 685.25 (+2) 
 
0.01 
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Sequence of the glycated peptides (* = glycation site) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EK*VLTSSAR (Lys 186) 14 1 1529.69 765.84 (+2) 765.85 (+2) 
 
-0.01 
ALK*AWSVAR  (Lys 210)15 1 1552.75 777.37 (+2) 777.37 (+2) 
 
0.00 
DTHK*SEIAHR (Lys 4) 16 1 1744.85 873.42 (+2) 873.42 (+2) 
 
0.00 
GACLLPK*IETMR (Lys 179) 17 1 1883.26 942.63 (+2) 942.63 (+2) 
 
0.00 
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It is essential to note that we have identified for both synthetic glycoconjugates 
the expected glycation site on Cys 34 residue, resulting from a Michael addition reaction 
between the TF antigen and the BSA protein carrier. Whereas, the direct conjugation of 
the TF ensued on the other -amino groups of the various lysine residues of BSA. 
Nevertheless, it was noted that for the two previously described trypsin digestions, we 
have identified a higher number of glycopeptides than one should expect, for a reaction 
performed with different stoichiometry of the TF:BSA ratio 2:1 and 8:1. This means that 
the uses of these different synthetic ratios result in neoglycoconjugates possessing 
different glycation occupancies. The net increase in the occupancy sites is caused by the 
presence of several numbers of glycoforms, formed during the synthetic carbohydrate 
carrier protein conjugation.
[38] 
This formation of glycoforms is not unforeseen as BSA 
contains several lysine residues which are free of steric hindrances and are 
straightforwardly available for other N-glycation reactions.   
For the purpose of illustration of the de novo sequencing of the formed 
glycopeptides, we have chosen to describe three examples. Henceforth, the product ion 
scans of the protonated molecules of the glycated peptides 5 (C-S glycation site is Cys 34) 
at m/z 1015.46(+3) (Fig. 3.3); 9 (C-N glycation site located at Lys412) at m/z 731.46(+3) 
(Fig. 3.4) and 4 (C-N glycation site is Lys12) at m/z 902.12(+2) (Figure B.1, 
supplementary material) are respectively described. 
 
 
 
 129 
 
 
 
 
 
 
 
 
Figure 3.3 CID-MS/MS spectra of identified glycated peptide 
GLVLIAFSQYLQQC*PFDEHVK 5 (Cys34) at m/z 1015.4614 (+3). 
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Figure 3.4 CID-MSMS spectra of identified glycated peptide K*VPQVSTPTLVEVSR 9 
(Lys412) at m/z 731.4685 (+3). 
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In addition, the formation of the diagnostic product ions obtained by the gas-phase 
CID-fragmentation of these protonated molecules of these glycated peptides 4, 5 and 9 
are presented in Tables 3.4, 3.5 and (Table B.1, supplementary material).  In this 
rationale, we have designated the carbohydrate product ions obtained by the MS/MS 
fragmentation of the glycopeptide protonated molecules the nomenclature generated for 
the B- and Y- ions product ions described by Domon and Costello,
[57]
 whereas for the 
peptide product ions, we have used the  b- and y- ions nomenclature of Roepstorff and 
Fohlman,
[58]
  
As hypothetically expected, we have noted for both digested glycoconjugates, the 
diagnostic formation of product ions corresponding to specific fragmentation of TF 
carbohydrate part, which is displayed in Figure 3.5. These product ions were 
characterized as follows: [B2 - Gal - CH2CO - 2H2O]
+
 at m/z 126.05, [B2 - Gal - CH2CO - 
H2O]
+
 at m/z 144.06, [B2 - Gal - H2O]
+
 at m/z 186.07, [B2 - Gal]
+ 
at m/z 204.08 and B2
+
 at 
m/z 366.14.  
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Figure 3.5 Product ions signature of the carbohydrate antigens, observed during the CID-
MS/MS analysis of the glycated peptides. 
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 A point of interest worth  mentioning, is that we have observed a difference in the 
CID-fragmentation  routes between the product ion scans of the two types of identified 
glycopeptides 5 (C-S glycation site located at Cys 34) at m/z 1015.46(+3) (Scheme 3.2), 
and 9 (C-N glycation site located at Lys 412) at m/z 731.46(+3) (Scheme 3.3). 
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Scheme 3.2 CID-MS/MS fragmentation of the TF-glycopeptide attached with the C―S 
bond at Cys 34. 
 
 135 
 
 
Scheme 3.3 CID-MS/MS fragmentation of the TF-glycopeptide attached with C―N bond 
at Lys 412. 
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 The CID-fragmentation of the (Cys 34) S-glycated peptide: 5 at m/z 1015.46(+3) 
afforded the series of products ions indicated in Table 4. This MS/MS analysis allowed us 
to identify the product ions formed by the carbohydrate hapten exclusively: [B2 - Gal - 
CH2CO - 2H2O]
+ 
at m/z 126.05, [B2 - Gal- H2O]
+ 
at m/z 186.07, [B2 - Gal]
+
 at m/z 204.08, 
B2
+
 at m/z 366.14, Y0
2+
 at 1341.11 and Y1
2+
 1442.63. Additionally, we also noted the 
peptide product ions resulting from the release of the carbohydrate portion from the 
glycopeptide protonated molecule [-B2
+
] and these were identified as:
 
[y5 - B2]
+
 at m/z 
261.30, [b7 - B2]
+
 at m/z 348.45, [y6 - B2]
+
 at m/z 408.37, [b8 - B2]
+
 at m/z 435.48, [b9 - 
B2]
+
 at m/z 563.54, [y8 - B2]
+ 
 at m/z 665.46, [b10 - B2]
+
 at m/z 726.60,  [b11 - B2]
+
  at m/z 
839.70, [y10 - B2]
+
 at m/z 921.57, [b13 - B2]
+ 
 at m/z 1095.81, [b14 - B2]
+
 at m/z 1255.84 and 
[b16 - B2]
+ 
at m/z 1499.96. Finally, we noted the products ions created by the forthright 
fragmentation of the peptide portion only: b2
+ 
at m/z 171.11, b5
+
 at m/z 496.34 and b17
+
 at 
m/z 1980.98.  
Finally, it is important to mention that for this above described MS/MS analysis of 
this glycopeptide ion at m/z 1015.46, no product ion containing the intact spacer linker 
arm was ever observed.  
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Table 3.4 Product ions obtained following the CID-MS/MS analysis  
of  GLVLIAFSQYLQQC*PFDEHVK 5 (Cys 34) ion at m/z 1015.46(+3). 
 
Product ion 
Calculated  
m/z 
Observed 
 m/z 
Error  
b17
+
 1980.98 1980.98 0.00 
[b16 - B2]
+
 1499.96 1499.96 0.00 
Y1
2+
 1442.66 1442.63 0.03 
Y0
2+
 1341.16 1341.11 0.05 
[b14 - B2]
+
 1255.84 1255.84 0.00 
[b13 - B2]
+
 1095.81 1095.81 0.00 
[y10 - B2]
+
 921.57 921.57 0.00 
[b11 - B2]
+
 839.70 839.70 0.00 
[b10 - B2]
+
 726.60 726.60 0.00 
[y8 - B2]
+
 665.46 665.46 0.00 
[b9 - B2]
+
 563.54 563.54 0.00 
b5
+
 496.34 496.34 0.00 
[b8 - B2]
+
 435.48 435.48 0.00 
[y6 - B2]
+
 408.37 408.37 0.00 
B2
+
 366.14 366.14 0.00 
[b7 - B2]
+
 348.45 348.45 0.00 
[y5 - B2]
+
 261.30 261.30 0.00 
[B2 - Gal]
+
 204.08 204.08 0.00 
[B2 - Gal- H2O]
+
 186.07 186.07 0.00 
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b2+ 171.11 171.11 0.00 
[B2 - Gal - CH2CO - 2H2O]
+
 126.05 126.05 0.00 
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On the other hand, the CID fragmentation for N-glycated peptides 9 (C-N 
glycation site is Lys 412) at m/z 731.46(+3) and 4 (C-N glycation site is Lys12) at m/z 
902.12(+2) are shown in Table 3.5 and (Table S3.1, supplementary material).  
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Table 3.5 Product ions obtained following the CID-MS/MS analysis of   
K*VPQVSTPTLVEVSR 6 (Lys 412) ion at m/z 731.46(+3) 
 
Product ion 
Calculated 
m/z 
Observed 
m/z 
Error  
Y0
+
 1828.35 1828.25 -0.1 
[y14 - B2]
+
 1145.84 1146.01 -0.17 
[b14 - B2]
+
 1099.82 1099.91 -0.09 
Y1
2+
 1015.17 1015.10 -0.07 
[y12 - B2]
+
 949.72 949.87 -0.15 
[b12 - B2]
+
 913.72 913.69 0.03 
[y11 - B2]
+
 821.66 821.74 -0.08 
[y10 - B2]
+
 722.59 722.65 -0.06 
y6
+
 702.41 702.42 -0.01 
[b10 - B2]
+
 685.61 685.75 -0.14 
[b9 - B2]
+
 572.53 572.65 -0.12 
[b14 - B2]
2+
 550.91 550.87 0.04 
y4
+
 490.26 490.25 0.01 
[b8 - B2]
+
 471.48 471.55 -0.07 
[y7 - B2]
+
 437.46 437.58 -0.12 
B2
+
 366.14 366.15 -0.01 
b3
+
 325.22 325.17 0.05 
y2
+
 262.15 262.13 0.02 
b2
+
 228.17 228.11 0.06 
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[B2 - Gal]
+
 204.08 204.07 0.01 
[B2 - Gal - H2O]
+
 186.07 186.06 0.01 
[B2 - Gal - CH2CO - H2O]
+
 144.06 144.41 -0.35 
[B2 - Gal - CH2CO - 2H2O]
+
 126.05 126.06 -0.01 
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To visualize the location of the glycation occupancies of the TF: BSA synthetic 
vaccines, we have indicated the complete sequence of BSA and the various glycation sites 
in Figure 3.6.  It is important to note that the three glycation sites of the TF: BSA 
glycoconjugate vaccine formed with a ratio of 2:1 are underlined. Whereas, the 14 
glycation sites are indicated with a red asterisk for the vaccine formed with a ratio of 8:1. 
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Figure 3.6 BSA sequence where the 14 glycation sites are indicated by red asterisk = 
identified peptides in TF:BSA ratio = 8: 1. The three underlined aminoacids = identified 
in TF:BSA ratio= 2: 1 and in TF:BSA ratio = 8:1. 
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The structure generated from the X-ray data of BSA (PDB access No. 3V03) 
using the software Discovery Studio v 3.1 is shown in Figure 7.  It is noteworthy to 
mention that the labeled Cys 34 and the 14 Lys residues are designated in the yellow and 
blue color respectively (ball and stick; C-S group of Cys 34 is in yellow, and the ε-amino 
groups of the Lys are in blue). Additionally, it is interesting to note that the characterized 
glycation sites proposed in this manuscript corresponded to the strerically non-crowded 
lysine and Cys 34 residues which were available for glycation by the hapten (Figure 3.7). 
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Figure 3.7 3D structure of BSA generated from the X-ray data using the software 
Discovery Studio v 3.1. 
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3.4 Conclusion 
In this work, we have determined the precise glycation sites of two different 
TF:BSA  (TACAs) vaccine prepared by a 1,4-conjugate addition (Michael reaction) 
between an acrylamide-ending TF (3) with BSA as carrier protein using a 0.2 M 
carbonate buffer for three days at either room temperature or at 40°C. This rationale 
reflects the attractiveness of glycoscience in the ability of using the free sulfhydryl group 
of Cys 34 of BSA as protein carrier for conjugation with TACAs but at the same time 
emphasize the fact that even the e-amino groups of the Lys residues can enter into such 
conjugate addition at proper pH, temperature, and reaction time. 
 Two synthetic neoglycoconjugate vaccines were prepared by the Michael 
addition reaction. Their molecular composition reflected exactly the stoichiometry found 
by our colorimetric analysis (Dubois test). These ratios were confirmed by MALDI-TOF-
MS analysis. De novo peptide sequencing using low-energy CID- MS/MS tandem mass 
spectrometry of the enzymatic digests allowed us to identify 3 glycation sites for the 
glycoconjugate prepared with a TF: protein ratio 2: 1 and 14 glycation sites for the 
glycoconjugate prepared with a TF: protein ratio 8: 1. All the identified glycation sites are 
located on lysine residues were the results of N-alkylation. However, this manuscript 
reports the formation of the unique C-S linked glycoconjugate identified exclusively on 
Cys 34.  
This systematic investigation constitutes a versatile example for the identification 
of accurate quality control necessary in commercial production of glycoconjugate 
vaccines. The glycopeptides isolated and fully characterized during this work may well 
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represent useful reference compounds to be used in standardization analyses. Moreover, 
although BSA usually serves a universal model carrier protein for novel conjugation 
chemistry, we found it perfectly legitimate as a vaccine in mouse experiments since the 
monoclonal antibodies isolated from the above conjugates were found to be anti-
metastatic.
[23]
 Most importantly, the identified glycopeptides may well form the basis for 
fully synthetic carbohydrate-based vaccines
.[2-5] 
This would be particularly true when 
performed on other more immunogenic protein carriers such as tetanus toxoid and KLH. 
Appendix B. Supplementary data 
Supplementary are data associated with this chapter (P.176) 
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Chapter IV: General Discussion and Conclusion 
 In the first part of this thesis, MALDI-MS was used for characterizing the changes 
of cryptocyanin protein from juvenile snow crabs during their molting and non-molting 
phases. It was demonstrated that the actual molecular masses of the non-molting and 
molting cryptocyanin proteins were different; these were 67.6 kDa and 68.1 kDa, 
respectively. In the second part of the thesis, the characterization of the exact glycation 
sites of a TF:BSA antigen was presented.  
 We have demonstrated for the first time in the literature that the actual molecular 
masses of the cryptocyanin protein of snow crab during the molting and non-molting 
phases were different. It was noticed that the molecular masses of cryptocyanin in other 
species were dissimilar. Accordingly, the molecular mass of blue crab (Portunus 
pelagicus) cryptocyanin was reported during the molting stage by using cDNA 
sequencing, and it was 50.1 kDa.
[1]
 In addition, Terwilliger reported the molecular mass 
of Dungeness crab (Metacarcinus magister) cryptocyanin during its pre-molting stage by 
using cDNA sequencing, and it was 78.3 kDa.
[2]
 The molecular mass of cryptocyanin 
from Metacarcinus magister was also previously assessed during development, molting, 
and physiological perturbations;
[3]
 the cryptocyanin molecular mass varied from 72.6 to 
77.3 kDa.
[3]
 Unfortunately, no information about the cryptocyanin molecular mass from 
these other species of crab is available for a comparison of masses between molting and 
non-molting stages, thus it is difficult at this time to make a comparison of the 
differencial findings with snow crab.  
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 Our results showed that the MALDI-CID-MS/MS analyses of the molting and 
non-molting cryptocyanin after tryptic digestion had some similarities and staggering 
differences between the identified cryptocyanin peptides. Our explanation is that a part of 
non-molting cryptocyanin, which was determined to be 513 Da, was lost during the 
molting process, which allowed the cryptocyanin to adopt new functions that are 
associated with the hardening the exoskeleton. It would be of future interest to compare 
the structure of the modified cryptocyanin with unmodified cryptocyanin to understand 
how the new functions arise. 
In the second study, it was observed that the majority of the glycation sites in the 
studied vaccine were located in the outer surface of the BSA. The importance of this 
discovery relies on the fact that the carbohydrate antigen is thus exposed and accessible to 
interact with specific receptors located on the surface of B cells. Three glycation sites -  
Lys 12, Cys 34, and Lys 535 - which were identified with TF:BSA ratio of 2:1, were 
completely accessible on to the surface of BSA. Nevertheless, only 11 glycation sites 
(Lys 4, Lys 12, Cys 34, Lys 106, Lys 116, Lys 127, Lys 179, Lys 186, Lys 210  Lys 522, 
and Lys 535) of 14 glycation sites with a TF:BSA ratio of 8:1 were accessible on the 
surface of BSA. Then, the three remaining glycation sites of the 14 glycation sites (Lys 
312, Lys 412 and Lys 429) were not accessible, but they were glycated because the BSA 
structure became less compact by an increasing in the temperature to 40
o
C during the 
glycoconjugate synthesis with TF:BSA ratio of 8:1. 
In both of the aforementioned studies, bottom up proteomics was  important for 
identifying large biological molecules, namely crab cryptocyanin and the TF:BSA 
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antigen. The application of MS/MS sequencing to the large biomolecules is considered a 
bright innovation in the field of protein mass spectrometry.
[4-6]
  
The two stages of bottom up proteomics, PMF and MS/MS ion searches, are done 
by the submission of the MS and MS/MS data of the digested protein to the Mascot 
library. While useful, the PMF method does have disadvantages, such that proteins with 
translational modifications resulting in mass shifts, partial proteolysis of proteins, and 
non-specific protein cleavages result in peptide sequences that cannot be identified using 
databases.
[4-9]
 Both PMF and MS/MS ion searches were used to identify the change to 
cryptocyanin during molting and non-molting stages. Cryptocyanin of snow crab was a 
previously unknown protein, thus the data obtained with PMF was vital to depict the 
different forms of cryptocyanin during molting and non-molting. As a result of using the 
peptide mass fingerprint database, the sequences of the digested peptides during molting 
were matched with other types of cryptocyanin in the Mascot library, thus leading to the 
discovery of snow crab cryptocyanin.  
For the data presented in Chapter III, PMF was not achieved in the determination 
of glycation sites of the glycoconjugate antigen. For determining the glycation sites of 
BSA in the glycoconjugate vaccine, PMF is unworkable because the BSA structure is 
altered by the conjugation of the carbohydrate antigen. However, a database search of 
ions obtained from the MS/MS spectra of glycated and non-glycated BSA was performed 
to elucidate the peptide sequences. The total sequence coverage for the free BSA, which 
is an important parameter to be considered in the proteomics field, was found to be in the 
range of higher than 90 %. However, the total sequence coverage for the hapten 
conjugated BSA was decreased to less than 50 %. The decrease in the total sequence 
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coverage reflects that some of the amino acid residues were mutated by the hapten 
conjugation, thus their peptides were recorded as non-matched peptides. Ultimately, the 
glycation sites were determined from the non-matched peptides using the Mascot library.  
 The proper choice of ionization source and analyzer type will depend on the 
nature of the sample.
[10-14]
 Accordingly, MALDI-QqTOF-MS was selected for the 
determination of changes in snow crab cryptocyanin protein because MALDI is well-
suited and highly sensitive for large biomolecules, and it additionally has a high tolerance 
for the salts and contaminants.
[12-18]
 Moreover, the MALDI spectra are easy to interprete 
because they contain singly charged ions.
[12,15]
 It was reported that MALDI has a 
suppression effect on the number of glycation sites during their determination in the 
glycoconjugates.
[8,19]
 For example, a recent study showed that the number of glycation 
sites in a glycoconjugate vaccine was 5 when determined by MALDI-CID-MS/MS, but 
using ESI-CID-MS/MS led to the identity of 30 glycation sites in the same vaccine. 
Accordingly, ESI was nominated as the ionization method for the determination of 
glycation sites in the glycoconjugate vaccine. 
 De novo sequencing of the glycated peptides of the glycoconjugate vaccine was 
achieved by using LC coupled with ESI-MS, and low-energy ESI-CID-MS/MS analysis 
with a QqTOF-MS/MS hybrid instrument. LC-ESI is a qualified technique for 
determining glycation sites, since the use of LC offers a separation method for digested 
peptides in a solution phase.
[12] 
ESI-QqTOF-MS was extensively used in previous studies 
for determining glycation sites of glycoproteins.
[9-12]
 Additionally, ESI-FTICR-MS and 
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ESI-QqTOF-MS were also reported for mapping and sequencing the O-glycosylated 
peptides.
[11]
 
 Ultimitely, the bottom up proteomics approach is based on database homology 
searches, so only matched sequences of proteins are recognized in the databases. 
Accordingly, a complete sequence of cryptocyanin was not achieved. Differentiation 
between two isomers, such as the amino acids leucine and isoleucine, can also be 
problematic in determining a peptide sequence, especially in the case of peptides with 
non-matched sequences in the homology database. Furtheremore, the MS analysis of 
glycoproteins is a complex task because the resulted spectra contain a structural mixture 
of carbohydrate and protein. A spectrum includes peptide sequences (b and y ions), 
carbohydrate fragments (B and Y ions), and spacer linked to peptide or carbohydrate 
fragments. 
4.1 Future aspects  
 Cryptocyanin has been sequenced by MS/MS and a signature peptide can be 
chosen to allow for the quantification of the protein. From the theoretical point of view, 
the signature peptide sequence should be free of Met and Cys, as these may be modified 
during the digestion of the protein by either the oxidation of the Met and/or 
carbomidomethylation of the Cys residue.
[20]
 As well, the empirical and technical 
properties of a signature peptide are based on the signal intensity of the peptide ions 
during the various mass spectrometric analyses,
[20]
 thus peptides with strong signal 
intensities would be preferred. 
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 Future work should include the study of other crab species, such as Portunus 
pelagicus and Metacarcinus magister, to compare cryptocyanin protein and RNA 
sequences between molting and non-molting stages.  Furthermore, because of the 513 Da 
difference in snow crab cryptocyanin mass between molting and non-molting, additional 
work with snow crab will be necessary, to identify whether the difference exists at the 
RNA level or just the protein level. 
 The use of the methods in Chapter III to identify glycation sites could be applied 
to future studies of other synthetic carbohydrate-based antigens that use more 
immunogenic protein carriers (instead of BSA), such as tetanus toxoid and KLH. These 
different forms of antigens could be administrated in vivo to test their effectiveness. 
Additionally, different ion fragmentation approaches could be used for mapping the 
glycation sites of glycoconjugates, such as ECD or ETD (electron transfer dissociation), 
which confer the fragmentation of the peptide backbone and allow top down proteomics 
to be performed on the intact proteins.  
4.2 Conclusion 
 In this thesis, snow crab cryptocyanin protein was isolated by SDS-PAGE and 
analyzed using a MALDI-TOF/TOF-MS instrument. The purified cryptocyanin protein 
was sequenced using a ‘bottom up’ approach, and it was found that two different 
sequences for cryptocyanin exist during molting and non-molting. Furthermore, the exact 
glycation sites of the TF-BSA anitgen were determined by using an ESI-QqTOF-MS/MS 
hybrid instrument. The work of my thesis clearly shows the power of MS and how it can 
be used to sequence large biomolecules. 
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CHAPTER II: Differentiation between the crustacean cryptocyanin protein during 
molting and non-molting processes of the snow crab (Chionoecetes opilio) using matrix-
assisted laser desorption/ionization mass spectrometry and tandem mass spectrometry 
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Table A.1 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion of the 
peptide HAWAVATNKR at m/z 1082.5324 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
b8
+
 908.4719 908.4743 -0.0024 
b7
+
 780.3789 780.3793 -0.0004 
y7
+
 759.8805 759.8735 0.0070 
b6
+
 666.3303 666.3364 -0.0061 
b5
+
 565.3019 565.2887 0.0132 
b4
+
 494.2581 494.2516 0.0065 
b3
+
 395.1860 395.1832 0.0028 
b2
+
 324.1467 324.1461 0.0006 
y1
+
 175.1232 175.1184 0.0048 
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Table A.2 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide FGPPFPVRN at m/z 916.5099 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y7
+
 769.4282 769.4350 -0.0068 
y6
+
 712.4028 712.4135 -0.0107 
y5
+
 615.3532 615.3908 -0.0376 
b5
+
 546.2737 546.2716 0.0021 
y4
+
 518.2790 518.3080 -0.0290 
b4
+
 399.2076 399.2032 0.0044 
y3
+
 371.2279 371.2396 -0.0117 
b3
+
 302.1474 302.1505 -0.0031 
y1
+
 175.1242 175.1184 0.0058 
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Table A.3 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide DGNGAIIPFDEGR at m/z 1360.6744  
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y12
+
 1245.6289 1245.6217 0.0072 
y10
+
 1074.5231 1074.5573 -0.0342 
y9
+
 1017.5388 1017.5358 0.0030 
y7
+
 833.4111 833.4146 -0.0035 
y6
+
 720.3352 720.3306 0.0046 
y5
+
 623.2765 623.2778 -0.0013 
y4
+
 476.2148 476.2094 0.0054 
y3
+
 361.1842 361.1825 0.0017 
y2
+
 232.1455 232.1399 0.0056 
y1
+
 175.1251 175.1184 0.0067 
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Table A.4 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide GVQPDKRPFGYPLDRR at m/z 1744.8554 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y13
+
 1588.7451 1588.8225 -0.0774 
b14
+
 1570.7979 1570.8018 -0.0039 
b13
+
 1455.7718 1455.7749 -0.0031 
y10
+
 1248.6251 1248.6842 -0.0591 
b11
+
 1245.6323 1245.6380 -0.0057 
b10
+
 1082.5711 1082.5747 -0.0036 
b9
+
 1025.5579 1025.5532 0.0047 
y8
+
 964.2069 964.4881 -0.2812 
b7
+
 781.4403 781.4321 0.0082 
y5
+
 663.3499 663.3455 0.0044 
y4
+
 500.3033 500.2822 0.0211 
b4
+
 382.2101 382.2090 0.0011 
b3
+
 285.1502 285.1563 -0.0061 
y1
+
 175.1171 175.1184 -0.0013 
b2
+
 157.1012 157.0977 0.0035 
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Table A.5 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide FDAER at m/z  637.2853 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y3
+
 375.2041 375.1981 0.0060 
b3
+
 334.1609 334.1403 0.0206 
b2
+
 263.0970 263.1032 -0.0062 
y1
+
 175.1250 175.1184 0.0066 
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Table A.6 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide DPAFFR at  m/z 752.3832 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y5
+
 637.3498 637.3451 0.0047 
b4
+
 431.1894 431.1931 -0.0037 
b3
+
 284.1283 284.1246 0.0037 
b2
+
 213.0894 213.0875 0.0019 
y1
+
 175.1205 175.1184 0.0021 
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Table A.7 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide YMDNIFR at m/z 958.4520 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
b5
+
 637.3027 637.2656 0.0371 
y4
+
 549.3283 549.3138 0.0145 
b4
+
 524.1718 524.1816 -0.0098 
b3
+
 410.1285 410.1386 -0.0101 
b2
+
 295.1124 295.1116 0.0008 
y1
+
 175.1248 175.1184 0.0064 
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Table A.8 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide RPHGYPLDR at m/z 1110.5552 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y8
+
 954.5277 954.4786 0.0491 
b8
+
 936.4587 936.4692 -0.0105 
b7
+
 821.4485 821.4422 0.0063 
y6
+
 720.3956 720.3670 0.0286 
b5
+
 611.3155 611.3054 0.0101 
y4
+
 500.2613 500.2822 -0.0209 
b4
+
 448.2439 448.2421 0.0018 
y1
+
 175.1232 175.1184 0.0048 
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Table A.9 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide LNHEEFSYK at m/z 1166.5525 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y8
+
 1053.4593 1053.4631 -0.0038 
b8
+
 1020.4508 1020.4427 0.0081 
y7
+
 939.4425 939.4201 0.0224 
b7
+
 857.3710 857.3794 -0.0084 
y6
+
 802.3564 802.3612 -0.0048 
b6
+
 770.3943 770.3473 0.0470 
y5
+
 673.3194 673.3186 0.0008 
b5
+
 623.2894 623.2789 0.0105 
b4
+
 494.2407 494.2363 0.0044 
b3
+
 365.1912 365.1937 -0.0025 
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Table A.10 Identified product ions obtained by CID-MS/MS of the [M+H]
+ 
ion obtained 
from the peptide VYEDIRDPHLK at m/z 1384.7427 
 
Product ion Observed Calculated Deviation 
  m/z m/z Da 
y8
+
 993.5187 993.5471 -0.0284 
b7
+
 891.3884 891.4212 -0.0328 
y7
+
 878.5179 878.5201 -0.0022 
b6
+
 776.4132 776.3943 0.0189 
y6
+
 765.4312 765.4360 -0.0048 
y5
+
 609.3241 609.3349 -0.0108 
b4
+
 507.2185 507.2091 0.0094 
y4
+
 494.2976 494.3080 -0.0104 
y3
+
 397.2605 397.2552 0.0053 
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APPENDIX B 
 
Additional Figure and table for  
 
CHAPTER III: Direct targeted glycation of the free sulfhydryl group of cysteine residue 
(Cys 34) of BSA. Mapping of the glycation sites of the anti-tumor Thomsen-Friedenreich 
neoglycoconjugate vaccine prepared by Michael addition reaction. 
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Figure B.1 CID-MS/MS spectrum of identified glycated peptide FK*DLGEEHFK 4 
(Lys12) at m/z 902.12(+2) 
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Table B.1 Product ions obtained following the CID-MS/MS analysis of 
 FK*DLGEEHFK 4 (Lys12) ion at m/z 902.12(+2) 
Product ion 
Calculated 
 m/z 
Observed  
m/z 
Error  
Y1
+ 1641.16 1641.10 0.06 
Y0
+ 1438.17 1438.11 -0.06 
y10
+ 1238.53 1238.54 -0.01 
y9
+ 1123.50 1123.51 -0.01 
[b12 - B2]
+ 1064.67 1064.67 0.00 
[y11 - B2]
+ 969.58 969.58 0.00 
[b11 - B2]
+ 917.59 917.59 0.00 
[b10 - B2]
+ 788.55 788.55 0.00 
[b9 - B2]
+ 673.52 673.52 0.00 
[y7 - B2]
+ 546.41 546.41 0.00 
[b8 - B2]
+ 513.49 513.49 0.00 
[y6 - B2]
+ 445.36 445.36 0.00 
[b7 - B2]
+ 400.40 400.40 0.00 
B2
+ 366.14 366.14 0.00 
[y5 - B2]
+ 332.28 332.28 0.00 
[b6 - B2]
+ 299.36 299.37 -0.01 
y2
+ 294.18 294.18 0.00 
b2
+ 242.18 242.18 0.00 
[B2 - Gal]
+ 204.08 204.09 -0.01 
[B2 - Gal - H2O]
+ 186.07 186.08 -0.01 
[B2 - Gal - CH2CO - 2H2O]
+ 126.05 126.05 0.00 
[B2 - Gal - CH2CO - 3H2O]
+ 104.04 104.04 0.00 
 
 
